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SUMMARY 
 
The objective of this work is to assist developing countries in designing their patent 
systems in order to promote biotechnology-based development. Many countries are 
unclear about how to tailor their patent regulations to promote their interests in the 
acquisition, development and application of biotechnology, and therefore how best to 
exploit the flexibilities of international law, especially the TRIPS Agreement. Two 
types of flexibility exist in Article 27.3(b) of TRIPS, which are a key focus of the 
present study: (i) the optional subject matter exceptions, specifically plants, animals 
and essential biological processes for the production of plants and animals; and (ii) 
the possibility to define these terms and others such as micro-organism in a variety of 
ways. 
 
Existing studies are very useful in linking the importance of IPRs, especially patents, 
to levels of development, and answering the question of what conditions in a specific 
country or industrial sector are necessary to ensure that IPRs foster, rather than 
inhibit, domestic innovation including ‘creative imitation’ and technology transfer. 
One inference is that it is only after countries have accumulated indigenous 
capabilities with extensive science and technology infrastructure to undertake creative 
imitation that IPR protection becomes an important element in innovation and 
technology transfer.  
 
However, few studies have focused specifically on biotechnology, and even fewer 
have linked biotechnological capabilities to implementation of TRIPS. This report 
seeks to fill this gap by focusing on relative biotechnology capabilities in different 
countries and linking such capability levels to a ‘menu’ of interpretative options 
arising from a close examination of the flexibilities of the relevant section of the 
TRIPS Agreement in order to achieve optimal outcomes.  
 
We started this project with great ambition. We wanted to lay out the full range of 
patent subject matter options available to developing countries and give some general 
impressions as to the policy-related implications of selecting one particular option 
over another (e.g. a broad or narrow interpretation of ‘micro-organism’). We hoped 
also to be able to develop a reliable ranking of developing countries according to their 
relative capacities in biotechnology. Having fulfilled these two tasks we intended to 
link these relative capacities to the interpretive options so as to generate optimal 
biotech patent regimes for each country. 
 
In practice this proved to be extremely difficult. The biggest challenge we faced was 
to find a way to objectively assess the biotechnological capacities of individual 
countries and then to use such an assessment to rank countries from lowest capacity at 
the bottom to highest capacity at the top. Unfortunately, we discovered that all of the 
indices devised and used so far are flawed. Therefore we adopted a more qualitative 
approach which sought to identify and draw inferences from general indicators of 
current capacity and future potential. We selected three countries which are 
considered to be relatively advanced, and one that is perhaps the most advanced of all 
developing countries in terms of biotech capacity and growth potential (India). We 
reckoned that if these countries have very limited capacity to innovate at the present 
time, then most of the developing world has minimal if any capacity at all. And this in 
turn suggests that they will gain little from a biotech-friendly patent regime and may 
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lose out overall in terms, for example, of having to pay out royalties and licensing 
fees that may be unaffordable. Consequently, the policy options for most developing 
countries as far as implementing Article 27.3(b) goes are quite simple: keep your 
subject matter inclusions narrow as possible and your exclusions as wide as possible. 
But for the most advanced developing countries, this may not be the most sensible 
option. While it is highly unlikely for these countries too that a US-style include 
everything and exclude nothing model would be at all helpful, a more nuanced 
calculation of where the lines should be drawn between patentable and unpatentable 
subject matters ought to be made. Again, this study should provide some guidance on 
how to do this. 
 
National policymakers in developing countries reading this report should ask 
themselves if their country’s biotech capacity is on the level of South Africa or 
Kenya, or below these countries. In such case, the TRIPS de minimis approach (what 
we call the “all exceptions option”) should probably be followed. Countries which 
have a capacity similar to that of India should study the “some exceptions option” and 
then figure out how best to put that option into effect. 
 
After a brief introduction, the report explains what we mean by biotechnology, 
discusses some of its commercial applications and explains why the relationship 
between patents and technological development, especially biotechnology, is very 
complex, very controversial and extremely important (Chapter 2). The following 
section (Chapter 3) explores and critiques the effectiveness of current methodologies 
available to form the basis for a ranking scheme for developing countries on relative 
biotechnological capacities that could offer pointers to the design of an optimal 
biotech patent regime. These are all highly limited if not flawed and so we present 
some plausible “rules of thumb” to be used as assumptions to make up for the 
deficiencies of these indices. We then continue with the three national case studies, 
which together reveal the severe lack of capacity of even the more advanced of the 
developing countries (Chapters 4-6). Chapter 7 comprises a detailed analysis of the 
language of Article 27.3(b) of TRIPS. On the basis of this analysis, Chapter 8 first 
casts doubt upon two matters: (i) that we yet have the tools to rank developing 
countries accurately; and (ii) that any more than a handful of developing countries has 
the ability to take advantage of patents to build up their biotech industries. More 
positively, though, it goes on to present the interpretative menu and discuss its 
applicability. We also offer some reflections on how patent policy making is 
conducted and ought to be conducted.   
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1. INTRODUCTION 
 
The overall aim of this study is to provide reliable guidance on how to design patent 
rules that are optimal in terms of enabling developing countries to participate in the 
‘biotechnology revolution’ and to thereby benefit their economies and populaces. 
Since most countries of the world are members of the World Trade Organization, the 
starting point of the study is the WTO’s Agreement on Trade-related Aspects of 
Intellectual Property Rights (TRIPS), which all members must comply with. 
According to Article 27.1, ‘patents shall be available for any inventions, whether 
products or processes, in all fields of technology, provided that they are new, involve an 
inventive step and are capable of industrial application.’  
 
Since biotechnology is obviously a field of technology, it is not possible to keep 
biotechnology out of the patent system altogether, whether or not to do so would be 
deemed as desirable. Nonetheless, it is important to understand that biotechnology is 
covered in the context of exclusions from patentability. Thus, Article 27.3(b) permits 
WTO Members to exclude from patentability: 
  
 plants and animals other than micro-organisms, and essentially biological 
processes for the production of plants or animals other than non-biological and 
microbiological processes.  However, Members shall provide for the protection 
of plant varieties either by patents or by an effective sui generis system or by 
any combination thereof. The provisions of this subparagraph shall be reviewed 
four years after the date of entry into force of the WTO Agreement. 
 
The problem is that many countries are unclear about how to tailor their patent 
regulations to promote their interests in the acquisition, development and application 
of biotechnology, and therefore how best to exploit these flexibilities.  
 
In essence, two types of flexibility exist in Article 27.3(b). These are (i) the optional 
subject matter exceptions, and (ii) the possibility to define the terms in a variety of 
ways. Clearly, the language of this provision is complicated. But it is also subject to a 
wide range of interpretations, a situation that allows policymakers to implement 
TRIPS in a very large number of possible ways.  
 
The challenges that subsequently arise are threefold. The first challenge is to identify 
all possible ways that Article 27.3(b) can be interpreted. The second is to identify the 
goals that governments wish to use their biotech-related patent rules to further. This 
must surely be based upon assessments of present biotech capacity of the country in 
question and of its future potential. The third is for government policymakers on the 
basis of such an assessment, and a decision on the goals it wishes to pursue, to select 
from our ‘interpretational menu’, as presented in our final chapter, the optimal patent 
rules available under Article 27.3(b). 
 
There is little doubt that countries will meet these challenges in a variety of ways. 
This should not surprise us. Developing countries, least developing countries and the 
former socialist nations together represent an enormous diversity in terms of socio-
economic conditions, levels of development, and potential. Consequently, 
accommodation of such diversity had to be built into the study.  
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A few clarifications and disclaimers are in order. First, patents are one among several 
legal and policy measures to promote local innovation and technology transfer and 
may not be the most important.  
 
Second, patent subject matter scope decision are not the only way to balance interests 
of all stakeholders and secure the best interests of the public. Patent systems should 
strike a balance so that the economic rights of inventors are sufficient to encourage 
invention, innovation and the dissemination of useful technical information, but not so 
excessive as to unduly hinder competition, stifle follow-on invention, or harm the 
public. Various measures are available to ensure that this balance is struck as 
optimally as possible. These may include:  
 
1) Subject matter exceptions, such as those that may be applied to drugs, 
software programs, business methods, plants and animals, whether or not the 
standard patentability criteria can be met 
2) Limitations to rights, such as compulsory licensing, government use 
provisions, research exemption and the ‘bolar’ (regulatory review) exemption 
3) The patent examination, which is supposed to ensure that what is disclosed is 
enabling, and what is claimed does not extend beyond what is disclosed 
4) Local working requirements 
5) Pre- and post-grant opposition procedures 
6) Morality/ ordre public objections 
7) Competition law 
 
This study only deals with the first of these. This might seem to make the study rather 
limited in terms of what it can achieve. However, biotech patenting subject matter 
flexibility is extremely broad in TRIPS and since implementation of this part of 
TRIPS continues to be under review at the TRIPS Council, producing evidence based 
policy guidance as to how developing countries may take advantage of the flexibilities 
is both necessary and timely, if not long overdue.  
 
One might add here that the existence, quality and size of the wider legal 
infrastructure, including patent practitioners, trained examiners, and well functioning 
courts is essential to make any patent system work. A balanced patent system in 
theory cannot become an optimal patent system in practice without these. But dealing 
with this issue falls beyond the scope of the study. 
 
Third, this study takes no position on specific biotechnological applications that some 
might endorse while others would deem them to be dangerous, immoral or otherwise 
inappropriate. Neither does it insist that countries should prioritise biotechnology-
related research and development over other fields of technology or industrial sectors. 
But we do accept that biotechnology has lots of potential and ought to be promoted, 
and that in any case WTO members are required to make patents available for at least 
some biotechnological inventions. Nonetheless, we do not take it as axiomatic that 
what is good for the biotechnology industry is good for the public. 
 
This study provides some useful guidelines on how to design optimal patent regimes 
for biotechnology within the confines of what TRIPS allows. That is about as far as 
we are able to go. But at the very least, our research shows how complicated it is to 
achieve efficient patent regimes especially in new fields of technology, and highlights 
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the failure of policymaking generally to take into account the complexities. Another 
inference of the present study is that technical assistance providers and others 
claiming to be authorities on how to design biotech patent regimes sensitive to the 
specificities of individual countries should be urged to provide convincing objective 
evidence for their prescriptions. 
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2. BIOTECHNOLOGY, THE LIFE SCIENCE INDUSTRIES AND INTELLECTUAL 
PROPERTY 
 
What is biotechnology? 
 
Biotechnologies are not only new and cutting-edge but also very old. This becomes 
evident if, as some experts do, one divides biotechnologies into three generations. The 
first generation includes traditional technologies like beer brewing and bread making, 
which goes back thousands of years, and the second begins with the microbiological 
applications developed by Louis Pasteur ‘based on the germ theory of disease’ 
culminating in the mass production by fermentation of the antibiotics. Tissue culture 
and modern plant and animal breeding also fall within this ‘generation’. The third 
generation biotechnologies, or ‘the new biotechnologies’, includes the various genetic 
engineering techniques for transferring DNA from one life form to another to make 
transgenic organisms expressing new and useful traits. The first such technique, 
known as recombinant DNA (‘rDNA’), was invented in 1973 by Stanley Cohen at 
Stanford University and Herbert Boyer at University of California at San Francisco 
(UCSF), and patented by the former university. The technique enabled foreign genes 
to be inserted into microorganisms and passed on to others through cell division. 
Since then other genetic engineering techniques have been invented. This latest 
generation also includes hybridoma technology,1 polymerase chain reaction (PCR)2 
and cloning. The present studies deal mainly with the second and third generations, 
especially the latter. 
 
The 1980 US Supreme Court decision in Diamond versus Chakrabarty, famous as a 
landmark decision for the patenting of life forms, claimed an engineered bacteria that 
was capable of breaking down oil products, and thereby clear up oil spills.  
 
The first commercial breakthroughs in biotechnology were seen in the pharmaceutical 
industry with products such as human insulin, growth hormone (GH) and 
erythropoietin (EPO). These were synthesised by bacteria that included human genes. 
These products avoided problems encountered with the previous forms of the drugs, 
such as incompatibility in the case of insulin because of impurities that resulted from 
the method of extraction as it was gathered from pigs, viral infection in the case of 
GH, or the extremely low amount of production for EPO.  
 
From its beginnings in the use of micro-organisms as a factory for the production of 
compounds of interest, modern biotechnology evolved toward the use of life forms as 
such with enhanced capabilities. Breakthroughs such as the discovery of Bacterium 
tumefasciens allowed biotechnology to affect much bigger organisms, plants in that 
case.  
 
                                                
1
 Hybridoma cells result from the fusion of a type of cancer cell known as a myeloma with another 
antibody-producing cell. Hybridomas produce multiple antibodies of a highly specific type, which are 
called monoclonal antibodies. The technology, which was developed in 1975 by Georges Köhler and 
Cesar Milstein, working in Cambridge at the Medical Research Council’s Laboratory of Molecular 
Biology, has considerable potential in both diagnostics and therapeutics. 
2
 PCR technology provides a means rapidly to replicate potentially vast quantities of a selected DNA 
section in a test tube. PCR is an extremely valuable research tool with many applications including 
genome sequencing and diagnostics. 
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In the biomedical industry, the use of biotechnology can be seen at various levels. 
Apart from insulin, GH and EPO, engineered bacteria are being used for the synthesis 
of safer compounds, later used as drugs. Animals are currently especially valuable in 
the creation of models for the analysis of disease.  
 
Based on the current definition of biotechnology, which is genetic engineering, there 
are two main distinctions: the resource or gene construct of interest to be inserted and 
the technology capable of inserting such gene or set of genes toward the realization of 
the objectives.  
 
The identification of genes of interest requires prospecting and access to resources; 
how extensive this has to be is dependant on the objective of the activity. The 
identification as such of the source of the trait of interest, the gene, will require a 
certain know-how and technological capacity. Once one is in possession of the gene, 
then the mechanisms of insertion will also de different depending on the subject 
matter.  
 
While it is a common practice nowadays to insert genes into bacteria toward the 
realisation of one’s objective, the complexity of macro-organisms makes the 
feasibility of attaining the predicted effect more complicated. Hence it might 
necessitate an even higher level of expertise and know-how, again associated with 
further technological capacities. Finally, once the objectives are realised, the 
specificities of the output will be at stake, opposing processes with products. In the 
case of insulin, GH, cheese, soy sauce, it is the product that holds value, but its 
enhanced features cannot be reproduced as such from the product. It is the process 
that constitutes the limiting factor. Hence the control or property will generally be 
enjoyed at the level of the process.  
 
In the case of genetically modified organisms such as the oncomouse, Bt cotton, 
golden rice, while the process is itself complex but capable of being reproduced, it is 
the product that becomes problematic. The final outcome, being a living organism, is 
capable of duplication. Also, the duplication can be achieved at very low costs and 
without any specific technological advances. Indeed, general farming practice for the 
reproduction of plants or animals could be sufficient. It has to be noted that the 
enhanced features of those organisms might not be passed toward the offspring with 
the same efficiency; this will be dependant on the organism in question. Wheat, soy, 
green beans, tomatoes, for example, are considered as fixed varieties with pure 
lineage with the consequence that they tend to reproduce identically to themselves, 
and are therefore easy to reproduce identically within normal farming capacities. 
While the control will still occur at the stage of the process, which is already limiting 
because of the technological requirements, it will also be at stake at the finality of the 
product, being more easily reproduced. A response from the industry against the latter 
problem was the development of the infamous terminator gene that provided a 
technological restriction against the plant duplication in traditional farming methods.  
 
Overall, most government funding and commercial activity relating to the new 
biotechnologies has been in the area of health. Health biotechnology is not only used 
to develop new types of drug but also in diagnostics and to enhance the efficiency of 
the drug discovery process. In fact, the latter has become the main objective of health 
biotechnology research. The types of product being developed include so-called 
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‘biopharmaceuticals’ such as genetically-engineered therapeutic proteins and 
vaccines. Other common types of product are diagnostic kits for diseases linked to 
genetic defects. 
 
Comparatively speaking, agricultural biotechnology is a much smaller field in the 
United States and Europe though it is a high priority for some developing countries, 
such as India and Kenya, which are heavily dependent on the viability of agricultural 
sectors for food security and employment, and in many cases, foreign exchange and 
political stability. Much of the research done so far has been geared towards the 
development of new seed products with introduced traits providing mainly agronomic 
benefits such as disease resistance, pest resistance and herbicide tolerance, and also to 
extend shelf-life of harvested produce. Little of the research has been directed so far 
at improving output quality for the benefit of consumers, although this situation is 
beginning to change. Unlike the healthcare case, there are relatively few agricultural 
dedicated biotechnology firms, even in the USA.  
 
In the livestock industry, the development of transgenic animals is occurring as well. 
But the applications are still very limited. While the technology should be sufficient, 
it is mostly a matter of consumer perception. Where the development and 
commercialization of transgenic plants induced fierce public debate and actions 
against such crop and practice at large, it follows that the issue will be even more 
problematic if addressed over livestock, which are viewed as closer to mankind.  
 
The food processing industry is also quite acquainted with biotechnology. A great part 
of the processed food results from the interaction of raw material with micro-
organisms (cheese, yoghurt, soy sauce, beer, and so on…). Hence, innovation occurs 
nowadays by improving the characteristics of those micro-organisms towards certain 
industrial objective such as the optimization of production or increase in quality of the 
processed product. 
 
Healthcare products tend to be most commercially attractive. This is because they 
have potentially much higher returns, and because demand tends to be much less 
cyclical. Most of the remaining biotechnology companies provide industrial or 
environmental products and services such as industrial enzymes and pollution 
diagnostics. 
 
In terms of future trends and opportunities, it is likely that sequencing and analysing 
human, animal, plant and microbial genomes and proteomes will take less and less 
time and money, suggesting ever-lowering barriers to entry. This increases the 
possibility that a few developing countries like India, China and Brazil will become 
major sources of innovations in this field in the coming years. 
 
What is the biotechnology industry, and what does it do? 
 
The ‘biotechnology industry’ is not a discrete industrial sector. Rather, there are firms 
that do nothing but biotechnology, and other companies, universities and public 
research institutes that conduct biotechnological work but do not specialize in it. The 
new biotechnology and genomics revolutions have created completely new 
commercial opportunities, and spawned four types of business. These are (i) the 
technology providers who manufacture the DNA sequencing machines and other 
 11 
equipment; (ii) the information providers that collect and organize sequencing 
information; (iii) the research firms, consisting mainly of the firms that generally do 
the upstream research but lack the resources or the ambition to do the downstream 
product development and marketing; and (iv) the health, agricultural and industrial 
biotechnology firms. These include the larger vertically integrated firms, and much 
longer established businesses, which are mostly pharmaceutical, chemical and life 
science corporations. These business types are not necessarily discrete. For example, 
Millennium Pharmaceuticals and Human Genome Sciences are also involved in drug 
discovery and development. 
 
To date much if not most of the basic research in biotechnology and genomics has 
been financed and conducted by governments, universities and private foundations. 
But private sector investment has increased in recent years, especially in the United 
States where commercial biotechnology really began. There are various reasons why 
the US has dominated from the start. Two important ones are the considerable amount 
of related state-funded basic research that had already been conducted by the 
universities and government agencies, and the large quantities of venture capital funds 
that are available to start up companies with a promising business plan.  
 
While the US system has been relatively effective at turning new discoveries made by 
public sector and university researchers into commercial products, Europe and Japan 
have been less successful in putting together the downstream linkages from 
fundraising for basic research all the way to commercialisation. However, since the 
1980s the European Community countries and Japan have been preoccupied with 
catching up with the US. Both the European Commission and the EU member 
governments have sought to stimulate biotechnology R&D through industrial policy 
and more business-friendly product and IPR regulation. So far they have been only 
partly successful, raising the question of whether developing countries can succeed no 
matter how carefully their IPR systems are designed.  
 
As for developing countries, quite of lot of our observations concerning innovation, 
investment motivations, business strategy and the role of intellectual property may not 
apply much if at all to them. All the more reason to conduct research on how best they 
should promote innovation taking into account these countries’ intellectual property 
obligations under international law.  
 
Patents, biotechnology and development: a crucial debate 
 
Article 27.3(b) has become an enduring subject for trade negotiations and NGO 
activism on TRIPS. Undoubtedly, this part of TRIPS is extremely important for 
developing countries. What is less clear is how they can take advantage of its 
provisions to further their sustainable development objectives. The situation is not 
helped by disagreement on what the paragraph actually means. In addition, many 
developing countries find themselves in circumstances that make it difficult to plan 
for the future and therefore to tailor their policies to specific development goals. So it 
is hardly surprising that they are unsure about where their national interests lie with 
respect to the paragraph’s provisions.  
 
While TRIPS does not allow WTO members to exclude biotechnological inventions 
from their patent systems in any explicit sense, Article 27.3(b) allows them to use 
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their discretion in determining the extent to which inventions in this technological 
field can be protected. The problem facing developing countries is that if they lack a 
clear idea of how biotechnology can benefit their economies and improve the lives of 
their citizens, they are in no position to design an IPR system to promote welfare-
enhancing biotechnological innovation. Moreover, many of these countries have no 
biotechnology industries to speak of, and there is every reason to be highly sceptical 
that such businesses will spring up just because life-forms and micro- and non-
biological processes can be patented. 
 
Another reason why it is difficult for developing countries to come up with a common 
position on the review of Article 27.3(b) is that they vary so much in their national 
capacities to generate or apply biotechnological inventions. Policy makers in the more 
technologically-advanced developing countries who believe that the new 
biotechnologies can be beneficial should design their IPR system with the goal of 
encouraging domestic innovation and technology transfer, and attracting funds for 
start-up firms. The experience of developed countries suggests that a carefully-
designed IPR system could indeed stimulate innovation, although there is a real 
danger of a carelessly-designed one turning out to be worse than not having one at all, 
for example, by over-protecting upstream research and thereby inhibiting more 
applied downstream research, or by allowing large companies to control markets, 
raise prices, and distort research priorities. But for many, if not most other, 
developing and least-developed countries, it is difficult to see how strong IPR 
protection will encourage innovation if the capacity to do the necessary research is 
barely existent anyway. But how much empirical evidence do policymakers have on 
which to base their decisions? Not enough.  
 
Previous studies have linked the importance of IPRs, especially patents, to levels of 
development, and addressed the question of what conditions in a specific country or 
industrial sector are necessary to ensure that IPRs foster, rather than inhibit, domestic 
innovation (including ‘creative imitation’) and technology transfer. One inference is 
that it is only after countries have accumulated indigenous capabilities with extensive 
science and technology infrastructure to undertake creative imitation that IPR 
protection becomes an important element in innovation and technology transfer. 
However, few studies have focused specifically on biotechnology, and even fewer 
have linked biotechnological capabilities to implementation of TRIPS. This study fills 
this gap by focusing on biotechnology capabilities in different countries.   
 
Debate concerning implementation of Article 27.3(b) is part of a much wider 
controversy concerning biotechnology patenting. Critical literature has focused on a 
number of aspects. Perhaps the following five are the most significant. The first is the 
moral significance of assigning property rights over life forms and their parts. The 
second is the way that such patents are considered to challenge the basic criteria for 
patents. The third is the concern that basic research may be discouraged by the 
patenting of molecular biology research tools. The fourth is the concern that such 
patents promote ‘biopiracy’. The fifth is that patents on plants and plant breeders’ 
rights can or at least may infringe the basic right of farmers to save and exchange 
harvested seed. These are all important issues that need to be taken very seriously, 
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though they have been reviewed at some length already.3 Instead, this part of the 
report reviews the debate on the relationship between patents, both generally and in 
the specific field of biotechnology, and innovation, technology transfer and 
development, while taking into account the specific characteristics of the 
biotechnology business.  
 
Patents are supposed to enable creativity and innovation to develop in an optimum 
manner. By providing an incentive to invent and to disclose invention, patents help to 
make R&D and the marketing of research outputs into commercially viable activities. 
Arguably, this function is workable at any stage of economic development. Hence, it 
is sometimes claimed that patents will promote innovation in developing countries, 
first by ensuring that there is a proper system in those countries to nurture their own 
innovative development, but also, by securing foreign investment as well as transfer 
of technology from other countries.4   
 
On the other hand, even if we accept that patents help ensure a sustainable stream of 
innovation, in addressing the interest of developing countries with respect to foreign 
technology it could also be argued that the development of an innovative system starts 
with copying. Freedom to imitate in a non wealthy environment, it is argued, should 
ensure the rapid diffusion and uptake of foreign technology or information. Under that 
assumption, strong patents may be counter effective. Then large scale creativity as 
such might first be experienced under creative imitation that soon will turn to proper 
innovation, which supposedly is sustained thanks to patents. The proper growth of a 
country in term of its technology might require patent regimes to adapt consequently. 
 
Plausible as that may seem, copying may not always result in full access to the 
technology. Indeed, according to the nature of the technology, transfer often requires 
the active participation of its owner. To protect the accessed information might then 
be a prerequisite for effective transfer of technology. In addition, the specificities of 
each technology make the association between patents and innovation even less 
predictable. Biotechnology includes a complex set of industries and implications, and 
both arguments could hold. Because of the complexity of the technology, its transfer 
will frequently require the cooperation of the holder of the technology, at least if one 
is considering capacity building and technology transfer. On the contrary, its output 
might be easily copied, as an example transgenic seeds can be reproduced through 
basic agricultural methods. Hence, copying might ensure that the agriculture of those 
countries takes advantage of the advance of developed countries without bearing the 
costs. Also, it will avoid control from developed country on the agriculture of 
developing country, which can be seen as a matter of food security. On the opposite, 
the development of plants of interest that suits the country natural conditions might 
need the developer to specifically invest for such country; cost that he will not bear if 
his investment is not protected within the recipient country.  
 
As with other science-based sectors, the road leading from basic research to product 
development is long, winding, and has many branches, some of which may be short 
cuts but are mostly dead ends. It is also very expensive to use, especially as journey’s 
                                                
3
 See Dutfield, G. (2004) Intellectual Property, Biogenetic Resources and Traditional Knowledge, 
London: Earthscan. 
4
 Park, W.G. & D. Lippoldt (2005) International Licensing and the Strengthening of Intellectual 
Property Rights in Developing Countries during the 1990s, OECD. 
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end approaches. And the companies best equipped to carry a product to the end of the 
road are not necessarily the most competent to start the journey, just as the front 
runners are often ill-equipped to complete the course.  
 
This situation provides both obstacles and opportunities for business. For new start-up 
firms it is hugely difficult to transform themselves into biopharmaceutical 
corporations. The opportunities lie in the fact that as the big firms concentrate on their 
core competences they outsource more and more tasks that may be essential elements 
of the research and development (R&D) process. Therefore niches are created that 
new small and medium-sized science-based firms can occupy profitably.  
 
Arguably, biotechnology patents encourage such a diversification of business activity 
by stimulating the foundation of small but highly-innovative firms and then by 
helping them to survive and remain independent. It has always been crucial to have 
access to large amounts of investment capital just to stay in business. Patent portfolios 
are the main magnet for outside investors – which also include larger science-based 
firms – and the larger the portfolio, the greater the interest from investors. In common 
with other industries, patents also become a form of currency in inter-firm 
transactions. It is sometimes claimed that research decisions in many companies can 
depend as much, if not more, on the advice of patent lawyers as the opinions of the 
scientists. Naturally, companies have a strong interest in securing patents that 
encompass the broadest possible scope and whose claims are drawn in ways that seek 
to anticipate future scientific developments. 
 
But there is a danger in the increasing dis-integration of the genomics innovation 
chain. For new firms that provide genetic information to the drug development firms, 
what they sell are to them final products but to their customers further down the chain 
are mere research tools. In order to protect these ‘products’ – and to secure funding to 
produce further ones – the firms have a strong incentive to privatize their information 
through IPRs. But since the development of future commercial products such as 
therapeutic proteins or genetic diagnostic tests often requires the use of multiple 
research tools such as gene fragments, an increasing number of which are being 
patented, companies intending to develop such products will need to acquire licences 
from other patent holders. In doing so, they will incur large (and possibly prohibitive) 
transaction costs. To return to the road metaphor, the danger is that more and more 
tollgates will be installed making the journey ever more expensive and excluding 
more and more potential travellers. So not only is the product development race 
becoming a relay race with more and more runners, but each runner is being forced to 
pay for the privilege of receiving the baton from the previous runner. The question is, 
will this slow down innovation and lead to fewer products on the market than would 
otherwise be available? And if so, how should the regulation of innovation through 
intellectual property protection be re-contoured in response? And what about 
developing countries? 
 
It is often observed that developing countries tend to be rich in biodiversity but poor 
in biotechnology. That is a gross simplification though in many cases it contains more 
than just a grain of truth. In that light, it can be argued that for many developing 
countries, the challenge facing them is to improve their life-science R&D and 
production capacities so as to take better advantage of the resources at their disposal. 
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The second is to identify, develop and mark high-value primary and semi-processed 
products.  
 
A static understanding of the principle of comparative advantage might lead us to 
suppose that while option 2 is feasible, biodiversity-rich developing countries need 
not consider attempting option 1, and have little alternative other than to export raw 
biological material. This generalisation is quite sweeping, and is unlikely to be true 
for those developing countries that are relatively advanced in science, technology and 
industrial development. Nonetheless, one must be cognisant of the very real obstacles 
to following option 1, especially the huge investments in training, education, and 
advanced R&D facilities that would be required.  
 
Encouraging the three ‘bios’: biotrade, bioinnovation and biotechnology transfer 
 
Enhancing the scientific and technological bases of developing countries requires 
appropriate regulatory and legal frameworks providing rewards and incentives for 
innovation and investment. The task for developing countries is, one can argue, to 
follow successful former developing countries like Japan and South Korea by 
transforming their comparative advantage from producing low-value commodities to 
high-value goods and services while increasing employment possibilities for the poor 
and not just for the well educated.  
 
While science-based research-intensive industries and technologies like 
pharmaceuticals and the new biotechnologies are extremely important, competitive 
high value-added products can of course be developed without cutting-edge scientific 
knowledge and equipment. High-value products may succeed in the market based on 
knowledge acquired from such sources as traditional communities. Products will 
command high prices in international markets only if they are knowledge-intensive, 
but this does not by definition require them to be science-based, high-tech, R&D 
intensive. In fact, various kinds of knowledge must be acquired and used for any 
product to succeed in the increasingly competitive global economy. According to 
Mytelka and Tesfachew, these kinds of knowledge include: (i) product design; (ii) 
process engineering; (iii) quality control; (iv) management and maintenance routines; 
(v) knowledge about markets and investment opportunities; and (vi) skills and 
capabilities needed to undertake changes in products and processes, create networks, 
and sustain partnering activity.5 
 
Innovation as understood in this broad sense is essential for countries seeking to 
produce high value-added manufactured goods and commodities rather than low-
value raw materials.  Innovation connotes newness but it is possible to argue that an 
innovation for one company or national economy may not necessarily be innovative 
to another. Indeed, promoting innovation in developing countries also means 
facilitating the acquisition, dissemination, and (where necessary) adaptation of 
knowledge and technologies from elsewhere. Local innovation and technology 
transfer, thus, are inextricably linked. 
 
                                                
5
 Mytelka, L K and Tesfachew, T (1998) The Role of Policy in Promoting Enterprise Learning During 
Early Industrialization: Lessons for African Countries, UNCTAD, Geneva, 2. 
 16 
Although innovation takes place in all parts of the world, developing countries tend to 
be net importers of modern technologies. Consequently, for several decades, 
technology transfer has been a major priority for these countries. Industrial 
technologies are conventionally transferred through such formalised means as foreign 
direct investment (FDI), joint ventures and licensing, of which FDI is the main 
channel.6  
 
According to Roffe, formal private-sector7 technology transfer ‘is a commercial 
operation that takes place through firm-to-firm arrangements and involves flows of 
knowledge, be they embodied in goods (as in the sale of machinery and equipment) or 
in the form of ideas, technical information and skills (through licensing, franchising or 
distribution agreements). Technology transfer can take place at arm’s length, as in the 
case of the export of capital equipment or of licensing agreements between 
unaffiliated firms, or it can be internalized through the transfer of new production 
techniques within a transnational corporation, between affiliate firms’.8 In fact, a great 
deal of formal international ‘technology transfer’ takes place within the same 
companies. 
 
Informal technology transfers can also take place on a large scale and in those 
countries in the early stages of industrialisation these may be far greater in number 
than formal ones. By definition, informal transfers are not based on any monetary 
transactions or legal agreements.  
 
The relationship between levels of IPR protection and the volume and direction of 
inward technology flows is highly complex. According to Maskus,9 in countries with 
strong IPR protection and enforcement, transnational corporations are likely to favour 
technology licensing agreements and joint ventures. In countries with weak IPRs, FDI 
would be the favoured business strategy in overseas markets.10 But technology flows 
are nonetheless likely to involve a great many factors whose relative importance will 
vary widely from one country to another.  
 
What is the empirical evidence concerning the links between stronger IPRs, 
investment flows, R&D and technology transfers? In fact, the data produced so far are 
hardly conclusive and suggests that FDI decisions may depend on a host of factors 
including the general investment climate. A study by Maskus11 claimed some 
evidence of a positive correlation, while conceding that IPRs are one of several 
                                                
6
 Radosevic, S. (1999) International Technology Transfer and Catch-up in Economic Development, 
Edward Elgar, Cheltenham, at 28. 
7
 Governments are also involved in technology transfer. Informal and free-of-charge technology 
transfers are also possible. 
8
 Roffe, P. (1999) ‘Transfer of technology and competition policy in the context of a possible’. In: 
Picciotto, S. and Mayne, R. (eds), Regulating International Business: Beyond Liberalization, 
Macmillan Press, Basingstoke, pp 142-160, at 151. 
9
 Maskus, K. (2000) Intellectual Property Rights in the Global Economy, Institute for International 
Economics, Washington DC, at 123. 
10
 Similarly, Vishwarao suggests the possibility that gains for a developing country from lack of IPR 
protection would be ‘offset by strategic behavior by Northern firms who opt for technology transfer via 
subsidiary or monopoly production’. Vishwarao, S. (1994) ‘Intellectual property rights and the mode of 
technology transfer’. Journal of Development Economics, 44, pp 381-402, at 381. 
11
 Maskus, K.E. (1998) ‘The role of intellectual property rights in encouraging foreign direct 
investment and technology transfer’. Duke Journal of Comparative and International Law, 9(1), pp 
109-161. 
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factors that may facilitate technology transfers, and also that strengthening IPRs will 
involve unavoidable costs (in terms of legislation, administration and enforcement) as 
well as benefits for developing countries.12 A World Bank study was even more 
cautious and recommended further research before firm conclusions could be made.13  
 
Research by Kim on the experience of South Korea suggests that ‘strong IPR 
protection will hinder rather than facilitate technology transfer to and indigenous 
learning activities in the early stage of industrialisation when learning takes place 
through reverse engineering and duplicative imitation of mature foreign products’.14 
He also concludes that ‘only after countries have accumulated sufficient indigenous 
capabilities with extensive science and technology infrastructure to undertake creative 
imitation in the later stage that IPR protection becomes an important element in 
technology transfer and industrial activities’. 
 
Finally, while it is the private sector that will be most involved in external trade, 
governments have a vital role to play in capacity building and in creating a conducive 
institutional-regulatory environment to promote innovation from basic research to 
commercialisation, of which the patent regime is an important part.  
  
                                                
12
 Finger, J.M. & P. Schuler (1999) ‘Implementation of Uruguay Round commitments: the 
development challenge’. Presented at the WTO/World Bank Conference on Developing Countries in a 
Millennium Round, WTO Secretariat, 20-21 September, Geneva; United Nations Conference on Trade 
and Development (1996) The TRIPS Agreement and Developing Countries, United Nations, New York 
and Geneva. 
13
 Primo Braga, C.A. & C. Fink (1999) ‘International transactions in intellectual property and 
developing countries’. Mimeo. 
14
 Kim, L. (2002) ‘The protection of intellectual property rights and technology transfer: a developing 
country view’. Case Study for the ICTSD-UNCTAD Capacity Building Project on IPRs and 
Sustainable Development, Geneva, at 5. 
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3. DETERMINING THE BIOTECHNOLOGICAL CAPACITIES AND PATENT 
INTERESTS OF COUNTRIES: SOME METHODS AND ASSUMPTIONS 
 
Undoubtedly, developing countries vary considerably according to the capacity of 
their research institutions and businesses to put the new biotechnologies to work and 
generate innovations of their own. Bhagavan15 divides developing countries according 
to their science and technology (S&T) capacities. Thus, these countries are members 
either of the ‘strong’, ‘medium’ or ‘weak’ South. The Strong South includes such 
countries as Brazil, China, India and Mexico, which are moving into high-technology 
fields such as the third-generation biotechnologies. The Medium South includes 
Indonesia, Malaysia and Argentina, while the Weak South consists of most other 
countries which are as technologically dependent on the developed countries as they 
were before decolonization. Several developing countries, including India, China, 
Brazil and Cuba, have the capacity to use third generation biotechnologies. However, 
the overwhelming bulk of biotechnology applications even in these countries is of the 
earlier generations such as fermentation and tissue culture.  
 
Measuring biotechnology capabilities is important for a variety of reasons; for the 
purposes of the present study, two of these stand out: first, it is undisputed that if 
developing countries are to prosper they must build the capacity to take advantage of 
new technologies such as biotechnology. Secondly, understanding what biotech 
capabilities exist in a given country will be instructive in designing appropriate 
systems and institutions that bolster domestic innovation and encourage technology 
transfer. These twin reasons form the foundation for this enquiry. Of course, to 
determine the biotechnological capacities, one needs to select workable criteria and 
indicators.  
 
One can envisage a potentially useful schema for different developing countries 
which builds on the work of economists Sanjaya Lall and Linsu Kim. Such a schema 
could be based on (i) indicators of biotechnological activity derived inter alia from 
levels of research and development financed by productive enterprises and patenting 
activity, (ii) industrial performance, (iii) absorptive and innovation capacities, (iv) and 
biotechnology product, service and royalty and license fee trade balances. But this 
section of the report casts a sceptical light on the quantitative methods that such a 
schema would largely be based upon.  
 
Defining terms 
 
Innovation systems literature is at pains to distinguish innovation from inventiveness. 
According to Hall16, the efficient application of knowledge is the departure point. 
Innovation is the application of knowledge to achieve a desired outcome whereas 
innovativeness is the ability to create novel things, irrespective of whether they are 
used or not. Bell and Pavitt17 distinguish research capacity from technological 
                                                
15
 Bhagavan, M.R. (1997) ‘Introduction’. In: Bhagavan, M.R. (ed) New Generic Technologies in 
Developing Countries, Basingstoke: Macmillan Press, Basingstoke, pp 1-21, at 3-4. 
16Hall, A. (2005) ‘Capacity development for agricultural biotechnology in developing countries: an 
innovation systems view of what it is and how to develop it’, Journal of International Development, 
17, 611-630 
17
 Bell, M. and K. Pavitt (1993) ‘Technological accumulation and industrial growth: contrasts between 
developed and developing countries’. Industrial and Corporate Change, 2/1, 157-210. 
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capacity in that the former concerns the resources needed to conduct scientific 
research while the latter concerns those needed to manage technical change. This 
includes skills, knowledge and experience, institutional structures and linkages 
between various disciplines, organisations, enterprises and policy and regulatory 
bodies.  
 
Being concerned with factors that encourage domestic innovation, this WP 
necessarily enquires into the larger technological capacity rather than research 
capacity.   
 
Quantitative methods of measuring biotech capabilities 
 
Scholars and economists alike have over time proposed various methods of measuring 
technological capacity in countries. This section examines some of the proffered 
methods primarily to explore if any of the methods suit the purposes of the present 
study. This exercise is by no means meant to be exhaustive but rather indicative of the 
various perspectives technological capacity can be viewed from and the inherent 
difficulties in adopting particular methods.  
 
Patents 
 
Perhaps the most often cited method of measuring technological capacity in both 
developing and developed countries is the use of patents. In virtually all the composite 
indices discussed below, patenting forms an integral part in developing each index. 
Although patents may seem like the most straightforward and obvious indicators of 
technological capacity, their use is rife with complexity and difficulty. A study 
conducted in 2000 by Thompson on rankings of the most innovative companies by 
patent filings highlighted the difficulties in using patents as a measure of 
technological capacity. Foremost, is the question of what patent database to use. The 
study accentuated that different results are obtainable depending on the patenting 
authority used.18 The difficulty in applying patent statistics to rank companies is 
indicative of the more arduous task when the subject sample shifts from relatively 
straightforward organisations such as companies to countries; the problem is further 
compounded when comparing countries especially if they happen to be in different 
stages of development.  
 
Although the temptation to use domestic statistics when comparing patenting activity 
in countries may exist, the caution is that lack of homogeneity among different 
national patent legislation, procedures and practice will render results inaccurate. Use 
of an international patent system is generally considered more consistent over time 
and location.19 Some studies have used both national and international patent systems 
in comparative innovative capacity studies.20 The choice of international patent 
                                                
18
 See Thomson (2000) ‘Rankings of the most innovative companies by patent filings’. IBM was the 
top company when statistics from USPTO were used, while it did not feature when PCT and JPO were 
used where Siemens and Toshiba were top respectively. Siemens was top company according to EPO 
statistics while IBM was 9th and Toshiba did not feature in the top ten.   
19
 Earlier work comparing inventive activity using international systems include Dosi, G., K. Pavitt & 
L. Soete (1990) The Economics of Technical Change and International Trade. New York: New York 
University. See also Eaton, J. & S. Kortum (1996) ‘Trade in ideas: patenting and productivity in the 
OECD’. Journal of International Economics, 40(3-4) 251-278 
20
 See for example, Porter, M. & S. Stern (2000) ‘National innovative capacity’. 
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system brings us back to the initial problem. The use of a single international patent 
system assumes that firstly, the system is equally accessible to all the target study 
countries; secondly, that fees and procedures affect everyone equally and thirdly that 
the target countries are equally keen to use the selected international patent system.  
 
The USPTO’s patent statistics have been used in many studies to measure foreign 
countries’ technological capacity.21 For Porter and Stern, the justification is that the 
use of USPTO is a sign of innovations’ potential economic value given the high costs 
of patenting as well as providing a high standard of technical excellence. The 
downside of using the USPTO (especially for this WP whose target nations are 
developing countries) is that foreign individual investors and small firms are less 
likely to patent abroad especially in the US.  
 
The WIPO administered Patent Cooperation Treaty (PCT) system is more suitable 
when comparing developing countries’ technological capacity. The EPO is also a 
candidate but given that many applications passing through the latter are initially 
made through the former, using the PCT system seems easier to use for comparisons 
among developing countries.  The assumption is that of all the international patent 
systems, individuals, small firms and companies in developing countries are most 
likely to apply for patents through the PCT system not in the least because it is 
accessible in terms of both costs and procedure. The downside is that the system is 
only available to PCT members. In our case, all the study countries are PCT members 
therefore this does not present a problem as such. It has also been said of the PCT 
system that it is biased towards high technology industries; being concerned with 
biotechnology, this is not a problem for the purpose of this study. Another drawback 
of the PCT system is that many applications may not be new as the assessment of 
novelty is only made at the grant stage (although you have since 2004 the IPER, 
International Preliminary Examination Report). This presents the related problem of 
whether the statistics to use are the number of patent applications or the number of 
patents granted in which case using the PCT system would be irrelevant given that the 
PCT system does not grant patents as such. Related to this and to the use of patent 
statistics generally is that not all inventions are patented and some forms of creativity 
particularly in developing countries are not patented.22 Further, some patents are 
considered more valuable and important than others leading studies such as Bosworth, 
Filiou and Longland23 into developing weightings to rank inventions.  
 
Another approach is that of the triadic patent family. This entails the counting of those 
groups of patents on the same invention that are granted by three patent-granting 
offices, usually the US PTO, the European Patent Office and the Japan Patent Office 
which are of course the most important ones. According to Chow et al: ‘the triadic 
family concept aims to provide for an ever-increasing need for reliable patent 
statistics and high quality indicators in measuring the performance of the various 
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 See Pouris A. (1991) ‘Identifying areas of strength in South African Technology’. Scientometrics 
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22
 See Jewkes, J. (1969) The Sources of Invention, 2 ed. Macmillan who gives various reasons why 
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 Bosworth, D. Filiou, and M. Longland (2003) ‘Measuring the “Quality” of Patents’, London: UK 
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nations on a comparable basis. The triadic family patent measurement is proposed on 
the basis that counting patents filed at different offices eliminates the problem of 
home bias and of ensuring that only high value added innovation should be the basis 
for comparison’.24 After all, for businesses to go to the effort and expense of filing 
patent applications in all three offices on the same inventions, these must presumably 
be deemed as non-trivial inventions (to say the least).   
 
It is clear from the foregoing discussion that relying on patent statistics alone as a 
measure of countries’ technological capabilities is dangerous and would not yield any 
meaningful or accurate results. Primarily because of this, various complementary or 
alternative indices have been developed. Some of these are discussed below.  
 
Composite indices25 
 
Oslo Manual 
The 1992 OSLO Manual was the first attempt by the OECD to harmonise 
methodologies for collecting standardised information on innovation activities in 
firms. The manual served as a basis for the first ‘Community Innovation Surveys’ 
(CIS) conducted in thirteen EU states in 1994 and has since been revised. The Oslo 
Manual measures R&D and patenting activities as well as non-R&D inputs and has 
been influential even in developing countries. However, discussions have been 
underway on how to adapt the Oslo Manual to the peculiar situation of developing 
country in order to take into account the largely informal setting for conducting 
innovation, the importance of incremental and organisational change and other 
features characterising innovation in developing countries.26  
 
ArCo (Archibugi and Coco) 
The ArCo Technology Index27 takes into account three main dimensions of 
technological capabilities which are weighted evenly: the creation of technology (with 
the subsets of patents and scientific articles); diffusion of technology (subsets are 
internet penetration, telephone penetration and electricity consumption); and human 
skill (subsets are tertiary science and engineering enrolment, mean years of schooling 
and literacy rate). Besides the already covered problem of using USPTO statistics, 
ArCo uses Science Citation Index for an alternative source of codified knowledge. 
Article counts are based on the country authors are from. It is not clear if this is their 
nationality or country of residence. This distinction is important given the ease with 
which scholars and academics change their residence. It is especially paramount 
where nationals of developing countries work outside the continent and vice versa. 
ArCo does not use resources on R&D ‘because the data in many developing countries 
are unsatisfactory’ and does not fit within the definitions developed under the OECD 
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Frascati Manual.28 There is no attempt to place this data in another subset; this 
information falls through the cracks.   
 
The UNDP Technology Achievement Index 
The main focus of UNDP TAI29 is to capture how well a country is creating and 
diffusing technology. The study uses data relating to 72 countries although it stresses 
that it is not a ranking of ‘technological might’ of a country. The index is made up of 
four main components: (i) the creation of technology is measured by patents granted 
per capita30 and receipts of royalty and licence fees from abroad per capita;31 (ii) 
diffusion of recent innovations which comprises of internet hosts per capita and 
exports of high and medium technology products as a share of all exports; (iii) 
diffusion of old innovations which is made up of electricity consumption per capita 
and telephones per capita; and finally (iv) human skills assessed by mean years of 
schooling and gross enrolment ratio of tertiary students in science, mathematics and 
engineering. All the components have equal weighting. 
 
The study acknowledges the lack of sufficient data but assumes that the lack of data 
on patents indicates that little innovation is occurring and consequently assigns a 
value of zero for missing indicators. In its formulation, TAI does not make provision 
for technologies and innovations occurring in the informal sector and in indigenous 
knowledge systems; it does however caution that this must be borne in mind when 
interpreting the values and rankings.  
 
Others 
The UNCTAD Innovation Capability Index focuses mainly on inputs – education and 
R&D. It has two main components: human capital index and technological activity 
index. The former is assessed by looking at (i) the literacy rate as a percentage of the 
population, (ii) secondary school enrolment as a percentage of age group and (iii) 
tertiary enrolment as a percentage of the age group. The technological activity index 
consists of (i) R&D personnel per million population (ii) US patents granted per 
million population and (iii) scientific publications per million population.  
 
The UNIDO Competitive Industrial Performance Index focuses on manufacturing 
competitiveness. The index is made up of four main components: manufacturing 
value added (MVA) per capita, manufactured exports per capita, share of medium and 
high- tech activities in MVA and share of medium and high-tech products in 
manufactured exports. This index’s main concern is technological capacity in industry 
and does not include other fields of technology. 
 
The World Economic Forum’s National Innovative Capacity Index focuses on  the 
institutional and policy environment for innovation. It consists of five components: (i) 
share of scientists and engineers per capita (ii) innovation policy (iii) cluster 
innovation environment (iv) innovation linkages and (v) operations and strategy.   
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 Ibid., at 8. 
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The World Bank Knowledge Economy Index has four main components: (i) the 
economic incentive and institutional regime which is assessed by tariff and non-tariff 
barriers, regulatory quality and rule of law; (ii) education and human resources which 
comprises of adult literacy rate, secondary enrolment rate and tertiary enrolment rate; 
(iii) innovation system made up of number of researchers in R&D, patent applications 
granted by USPTO and S&T journal articles and finally (iv) ICT infrastructure 
consisting of telephones,  computers and  internet users  per 1000 population. 
 
The Francisco Sagasti – S&T Capacity Index index consists of three main 
components: science, technology and production whose components are classified 
into internal capacity and external linkages. The science component has two sub 
indices: R&D expenditure as percentage of GDP and number of scientific 
publications. The technology component is made up of number of scientists and 
engineers per million people and number of patent applications by residents and non-
residents while the production component consists of high tech exports as a 
percentage of total exports and infrastructure, communications, and technology index.  
 
Less of an index and more of a list of factors to consider, UNU-INTECH32 lists 
measurement priorities with specific reference to developing countries: knowledge 
accumulated through human resources, procedures and routines; linkages, quality 
assurance systems and the incorporation of ICT; more complex issues for example 
types of decision-making support systems and firms’ actual potential for knowledge 
absorption.   
 
What the foregoing shows is that the choice of index is determined by the task and 
focus at hand. And even then, the most careful selection of indicators cannot yield 
absolutely accurate results.  
 
Soubbotina33 cautions on the use of composite indices and suggests considerations in 
selecting capacity indicators some of which are summarised thus: 
• Input and output indicators are selected depending on whether the aim is to 
measure technological effort or technological achievement 
• economies of scale and critical mass effect render absolute size of inputs as 
important as input intensity  
• Some indicators reflect current capacity while others reflect expected but 
uncertain future capacity  
• Indicators of knowledge sales reflect quality of knowledge rather than just its 
quantity 
  
Commentary  
 
The foregoing discussion reveals, first, that a country’s technological capability is 
composed of a variety of sources of knowledge and innovation and is larger and more 
complex than any index can encapsulate. Many aspects of innovation are difficult to 
quantify and even if quantifiable, there is always the problem of lack of reliable data 
particularly in developing countries. Important technology innovations in the informal 
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sector may not be recorded and therefore difficult to take into account in the 
formulation of an index the components of which are in their nature, definite values.  
 
There has been significant change in biotech R&D in the past two decades. Private 
sector involvement in agriculture and health, both in R&D and in product and service 
delivery, has become more entrenched. The role of the state has similarly changed 
with implications on research and delivery of research products. Above all, 
globalisation of knowledge, markets, regulatory and trade regimes has had pervasive 
implications on agriculture and health.  
 
Hall writes that the emergence of biotechnology is evidence of the change in the 
broader framework conditions under which S&T takes place. He identifies the critical 
features of biotechnology to include technological paradigm shifts, institutional 
changes including a greater degree of ownership of knowledge and new patterns of 
partnerships and science and society controversies surrounding ethical, environmental 
and health risks.34  
 
An effort to measure biotechnology capabilities would have to take into account these 
defining features. Biotechnology often has high R&D content and therefore traditional 
input and output indicators will be our starting point. An assessment of governance 
issues - laws and policies - will be crucial in understanding the environment under 
which innovation in biotechnology flourishes. An attempt will be made at exploring 
the synergy between organisations.  
 
Unlike most of the composite indices discussed above, this study’s approach is 
primarily qualitative rather than quantitative. Given the range and complexity of the 
data to be collected, we found it best to opt for a case study approach. We chose three 
developing countries: South Africa, Kenya and India. We use secondary data from 
reports, surveys and reviews to supplement information obtained from the interviews.  
 
Estimating the development-related patent interests of countries on the basis of 
levels of development 
 
According to Lall, there is evidence that ‘the need for IPRs varies with the level of 
development’. He then goes on to say that: 
 
Many rich countries used weak IPR protection in their early stages of 
industrialisation to develop local technological bases, increasing protection as 
they approached the leaders. Econometric cross-section evidence suggests that 
there is an inverted-U shaped relationship between the strength of IPRs and 
income levels. The intensity of IPRs first falls with rising incomes, as 
countries move to slack IPRs to build local capabilities by copying, then rises 
as they engage in more innovative effort. The turning point is $7,750 per 
capita in 1985 prices …, a fairly high level of income for the developing 
world.35 
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Of course, it is one thing to say that relatively advanced developing countries have 
preferred to weaken their IP rights in order to advance their capacities to innovate 
through imitation-derived technological learning. It is quite another thing to assume 
that such a policy works just because many governments have favoured it. 
Nonetheless, intuitively it makes a lot of sense. 
 
Let us then make four working assumptions to be tested in this study. But before 
doing so we introduce a caveat. This is that we do not accept that the optimal patent 
scope36 in terms of subject matter relates directly to indicators of income and output, 
such as gross national product (GNP). Optimal patent scope is more likely to be 
related to the capacities to absorb technological knowledge, to learn and to innovate. 
 
The first assumption is that least-developed countries that are inactive in the field of 
biotechnology would benefit most from keeping as much biotechnological invention 
out of the patent system, assuming conveniently that the fees acquired through the 
processing of biotechnology patent applications are insufficient to cover the costs of 
examining patents and making them enforceable through the court system. Second, 
low-middle income developing countries may find it beneficial to expand the extent to 
which biotechnology inventions are patentable so as to encourage investment and 
technology transfer. Such inventions might in many cases be difficult to copy anyway. 
However, they may wish to introduce certain limitations to the rights such as a fairly 
broad research exemption so that emerging local firms may be able to do some 
imitation without fear of litigation. Third, high income and technologically advanced 
developing countries with a much higher capacity to imitate would benefit from 
reducing the extent to which biotech inventions are patentable since the advantages of 
such imitation would compensate for any losses in terms of reduced investment and 
technology transfer. Fourth as developing countries join the ranks of developed 
countries, they become sufficiently innovative that they will find it advantageous to 
again extend the scope of biotech patenting in line with developed world standards. 
 
                                                                                                                                       
Sustainable Development, Geneva. (Citing K.E. Maskus, Intellectual Property Rights in the Global 
Economy, Washington DC: Institute for International Economics (2000), at 95-96.) 
36
 To clarify patent scope in this context does not relate to the breadth of individual patents, but to the 
extent of subject matter limitations. 
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4. SOUTH AFRICA 
 
 
Introduction 
 
South Africa has a well-developed economic and commercial sector which has been 
largely based on natural resources. The resources available for biotech in South Africa 
are limited with the proportion of the national budget directed towards biotech much 
lower than in developed countries. South Africa has firmly-established national 
priorities for utilisation of available resources resulting in strong government 
influence on research direction. The government has adopted biotech as one of the 
areas in which to focus its research support.  
 
Biotech in South Africa has until recently focused mainly on first-generation 
applications such as those in the food industry. There are well-developed industries 
involved in brewing and food production including a successful wine industry. More 
recently, activities around developing biotech industries focusing on chemical, 
pharmaceutical, industrial and environmental biotech have progressed rapidly 
particularly because of government prioritisation of biotech. 
 
Institutional framework 
 
Institutional actors in biotechnology R&D in South Africa include academic 
institutions, public research institutions, and industry. Academic institutions constitute 
the largest group of participants in biotechnology. They are engaged in both basic and 
applied research.  
 
The institutions charged with the development and regulation of biotech include the 
Department of Science and Technology (DST) which is the lead department in 
biotech. It coordinates biotech related research of all other departments and is a vital 
link to the Treasury. Medical research falls under the Department of Health which 
coordinates the National Bioethics Committee and advises the Biotechnology 
Advisory Committee. The Department of Trade and Industry supports innovation in 
industry and provides funding through incentive schemes. It also plays a crucial role 
in commercialisation of biotechnology. The Department of Agriculture implements 
the GMO Act and the Plant Breeders Act. It has a lead role in biosafety issues and 
advises the Biotechnology Advisory Committee. Other government departments with 
operations related to biotech include Department of Environmental Affairs and 
Tourism, the Department of Labour and the Department of Education. 
 
Research activity 
 
The 2003 National Biotech Survey37 identified 106 companies engaging in biotech 
related activities; of these, 47 were core and 59 non-core.38 Majority of the core 
biotech companies engage in human health. The rest are evenly distributed across the 
                                                
37
 Mulder, M and Henschel, T. (2003) National Biotech Survey 2003, available at 
https://www.oecd.org/dataoecd/7/37/36036991.pdf  
38
 Id.The study focussed on modern biotech companies, therefore leaving out those that engage in more 
traditional forms of biotechnology. 
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other sectors with the exception of the ‘other’ category which attracts only 3% of the 
core biotech companies. 
 
Figure 1: Sectoral distribution of core biotech companies 
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Source: National Biotech Survey, 2003 
 
In total, there are about 1000 projects relevant to biotechnology; these are spread over 
seven sectors and includes projects undertaken by both public and private sector. The 
National Biotech Survey classified the projects as biotech, potential biotech, 
fundamental research and biotech services according to their relevance to biotech. The 
sectoral distribution of research projects is represented below. 
 
Figure 2: Sectoral distribution of biotech research projects 
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Adapted from National Biotech Survey, 2003 
 
The largest sector is plant biotechnology where most of the biotechnology carried out 
in the sector is on crop improvement i.e. insect, fungal, viral resistance and herbicide 
and drought tolerance. Others involve indigenous plant utilization, fruit improvement, 
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forest tree improvement and micro-propagation, horticultural propagation, 
improvement of storage properties, weed control and yield and quality enhancement. 
 
In plant biotechnology, over 590 applications involving the commercial release, 
importation, exportation, contained use, trials and clearance of GM crops have been 
received and granted by the registrar of the GMO Act as shown below. 
 
Table 1: GMO permits issued by the Registrar under the SA GMO Act Dec’99 - 
June’03 
 
Applications 1999 2000 2001 2002 2003 
Commodity 
import 
1 6 3 37 4 
Import 0 50 64 58 19 
Field trials 2 45 61 50 1 
Export 0 3 22 36 34 
Transit 0 0 0 2 1 
Animal Feed/ 
Food 
0 1 3 1 1 
General Release 0 1 3 1 1 
Commodity 
clearance 
0 0 6 4 0 
Contained use 0 11 1 2 1 
Greenhouse 
trials 
0 0 2 1 0 
Commercial 
planting 
0 0 9 11 8 
TOTAL 3 122 172 219 73 
Source: SA Dept of Agriculture, 1999, 2000, 2001, 2002 and 2003 
 
According to a survey conducted by Webster and Koch,39  there is a limited number 
of new companies established that are solely biotechnology based. Most are small and 
medium sized enterprises (SMEs). There are also a few multinational companies 
especially in the seed sector. The majority of the 47 companies identified as ‘core’ in 
the 2003 survey comprise of either new start-ups or spin-offs from other enterprises.  
 
 
 
 
 
 
 
 
 
 
 
 
                                                
39
 Webster and Koch (1998) Biotechnology Survey: A Statistical Analysis of South Africa and Sub-
Saharan Africa. CSIR Internal Report. 
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Figure 3: Number of core biotech companies set up 1984 to 2003 against 
cumulative number of core biotech companies 
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With regard to geographic distribution, various studies40 show that the majority of 
research stakeholders are found in the Western Cape, Gauteng, KwaZulu Natal and 
Free State. The regional distribution of biotech research projects and core biotech 
companies mirrors this. 
 
Figure 4: Regional distribution of core biotech companies, biotech researchers 
and biotech projects 
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Adapted from National Biotech Survey, 2003 
 
 
                                                
40
 Bioventures, Catalyst Innovation Incubator, Acorn Technologies, and eGoli BIO studies conducted 
as of 2003. 
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Funding  
 
The total funding on biotechnology R&D has been raising steadily since 1997 when it 
was R100million; R200million in 2002 and in excess of R290 million in 2003.41 The 
2001 National Biotechnology Strategy proposed the set up of Regional Innovation 
Centres (RICs) under the Department of Science and Technology. DST committed an 
initial R450 million from 2004 to 2007 for biotech development.42 The Biotechnology 
Partnership for Africa’s Development (Biopad) was established in 2003 as a 
collective response by stakeholders in biotechnology to the biotech needs of the 
region and continent.43 In 2003, the government committed R250 over two years in an 
effort to boost Biopad led commercialisation of biotechnology. It pledged to increase 
R&D spending from 0.27% to 1% of national GDP.44 The biotechnology policy 
launched in 2004 looks towards forming strategic partnerships as the way forward in 
attracting investment. 
 
Funding from the private sector is limited. The impact of RICs and other technology 
incubators established under the national strategy on private sector investment is yet 
to be seen. It is hoped that there will be more incentive for increased private sector 
investment. Consolidation of the international seed industry has led to technology 
being held by a small number of multinational companies.   
 
Institutional linkages exist between South African institutions on one hand and local 
and international universities on the other.  These linkages are characterized by 
information and material exchange. There are other limited collaborations between 
national research institutes, international organizations, government departments, 
NGOs and the private sector. The need for improved institutional linkages was 
expressed by those interviewed. 
 
Venture capital has not taken much root in South Africa. There are however some 
public and private sources of venture capital funding for start-up companies wishing 
to engage in biotechnology. These include HBD Venture Capital, Bioventures, Brait 
Private Equity, Support Programme for Industrial Innovation, Technology and Human 
Resources for Industry Innovation, Industrial Development Corporation, Synexa Life 
Sciences, and Catalyst Innovations. Biotech firms are yet to be listed on the AltX or 
JSE Securities Exchange.45 
 
 
 
 
                                                
41
 Webster & Koch (1998) supra; Webster & Koch (2002) Biotechnology Sector Report. Implications 
of the Information Revolution for Economic Development in South Africa. DTI Policy Support 
Programme; National Biotech Survey (2003) supra. 
42
 SouthAfrica info (2003) Developing South Africa’s Biotech Industry. 
43
 See biopad website http://www.biopad.org.za/ 
44
 Maistry, P. (2003) ‘Modern biotechnology and genetic modification: bridging the gap between 
business and practice’. 
45
 SouthAfrica info (2004) SA’s Budding Biotech Industry, 5 January 2004 available at 
http://www.southafrica.info/ess_info/sa_glance/scitech/biotech-audit.htm. Companies need to have 
profits greater than R8 million before they can be listed on the stock exchange. Only 20% of biotech 
firms have revenue in excess of R10 million. 
 31 
Human resource development 
 
There are a significant number of scientists with postgraduate qualifications. In 1998, 
the figure was estimated at 1200, 20% of which had PhD qualifications and 20% with 
MSc degrees.46 The highest concentration of the qualified individuals is found in 
academic institutions. Loss of graduates and staff from the system has however lately 
been of concern as qualified personnel seek greener pastures in the private sector and 
abroad.  
 
The 2003 Survey identified approximately 1020 staff in biotech related activities with 
biotechnology companies showing a relatively even distribution of employees by 
qualification. This is probably a function of the averaging out of R&D personnel and 
technical/production staff in a sample that includes R&D intensive as well as 
production-orientated companies. As is to be expected, research groups are dominated 
by employees with at least a degree qualification, and frequently a post-graduate 
degree. 
 
The Survey reports that approximately 50% of companies and 81% of research 
stakeholders that participated in the survey indicated that they had experienced 
shortages in human resources. The majority of research stakeholders listed skilled 
scientists at various levels, particularly MSc’s and PhD’s, as being in short supply. It 
is expected that capacity for commercialization of biotechnology will improve with 
the implementation of the national strategy through the establishment of the RICs. 
 
Administration and regulation  
 
Until 2004, South Africa did not have a national biotech policy. National policies on 
areas that are related to biotechnology and biosafety such as the environment and 
agriculture, do not focus much attention on biotechnology and biosafety save for 
perhaps the National Policy on the Conservation and Sustainable Use of Biodiversity. 
This expresses the need to adopt measures to regulate the use, handling, transfer and 
release of GMOs. The 1996 White paper on Science and Technology underscores the 
role of science and technology in promoting South Africa’s economy and recognizes 
the benefits that science and technology offers in the improvement of the livelihoods 
of South Africans. It however only identifies biotechnology as an area of 
collaboration both nationally and internationally and across various partners.  
 
After numerous national pronouncements indicative of the political recognition of the 
opportunities offered by biotechnology, a national biotechnology policy was launched 
in September 2004. The policy47 identifies health, agriculture, industry, mining and 
the environment as priority areas. The policy also identifies need related to research 
infrastructure for the design, testing and manufacture of drugs and vaccines. It adds 
that human resource development must be promoted and greater capacity and 
awareness of the need and potential of bioinformatics is crucial.   
 
 
 
                                                
46
 Wolson, R. (2001) Agricultural Biotechnology Assessment in Sub-Saharan Africa, Country Study: 
South Africa. Report prepared for the African Centre for Technology Studies 
47
 DST (2004) Biotechnology Platforms: Strategic Review and Forecast, 9 September 2004. 
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The National Biotechnology Strategy 
 
In spite of South Africa’s long history in use of biotechnology and the large number 
of biotechnology-embracing projects, various stakeholder meetings determined that 
the potential of third generation biotechnology had not been maximized and that very 
few products and processes were under commercialization. The limiting factors were 
identified as including the lack of infrastructure for R&D, institutional capacity, 
business support and management for start-up technology companies, lack of 
technology platforms in science and technology, coordination of policies and 
programmes, lack of collaboration and funding for innovative ideas. In response to 
this, the Department of Science and Technology embarked on a study which resulted 
in the drafting and gazettement of the National Biotechnology Strategy for South 
Africa in November 2001.48  
 
The Strategy identifies gaps and suggests new institutional arrangements and specific 
actions to be taken by government departments. Key interventions currently being 
implemented as a result of the strategy include the creation of three Regional 
Innovation  Centres (RICs), creation of a National Bioinformatics Network to develop 
capacity and support services in bioinformatics, development of Biological Resource 
Centres to ensure the adequate protection and optimal use of biodiversity, 
establishment of the Biotechnology Advisory Committee to implement the strategy, 
coordinate R&D and address ethical issues, the establishment of a Bioethics 
Committee, promoting the public understanding of biotechnology and the 
development of a Biobank. 
 
Working groups of experts in human health, plant improvement, animal health, 
industrial processes and new biotechnology platforms are currently analysing 
information on opportunities, key technologies and market trends under the DST 
Biotechnology Roadmapping Project. The emphasis is on R&D, human resource 
development and infrastructure needs in the named areas. The working groups consist 
of experts from government, industry and academic institutions. 
 
Legal framework 
 
There is no specific Act of parliament regulating biotechnology in SA; rather, there 
are various Acts regulating biotech related activities. These include the GMO Act of 
1997 which covers biosafety issues relating to GM products. Agricultural products are 
regulated by the Agriculture Act of 1947 while the Biodiversity and Protected Areas 
Acts regulate the use of biodiversity for biotechnology. In the health sector, the 
Medicines Control Act of 1965 governs the registration and use of medical 
substances, while the Human Tissue Act of 1983 regulates the use of human tissue for 
research.49 Legal Guidelines for Research in Biotechnology, 2006 exist in draft form  
are intended to guide applicants from the initial considerations in respect of what 
research is permissible and how to obtain authorisation to conduct research to the 
final stage of commercialisation of the research by way of patent protection. The 
                                                
48
 South Africa National Biotechnology Strategy (2001). 
www.dst.gov.za/publications/reports/dst_biotechnology_strategy.PDF 
49
 The National Health Act of 2003 is set to replace the Human Tissue Act. A major departure is that 
the former will allow therapeutic cloning which is impermissible under the latter. 
 33 
corresponding Ethical Guidelines for Research in Biotechnology deal with ethical 
considerations.  
 
South Africa has five Acts of parliament addressing intellectual property. These are 
the Patent, Trademark, Copyright, Registered Designs and Plant Breeders’ Rights 
Acts. All are administered by the Department of Trade and Industry with the 
exception of the Plant Breeders’ Rights Act which is under the Department of 
Agriculture. The Patent Office is a non-examining office. For a country as advanced 
in innovation, at least by African standards, the intellectual property infrastructure is 
basic.50 The National Biotechnology Strategy highlights the requirements for a review 
of the patent legislation. 
 
Outputs and outcomes  
 
In spite of biotechnology being in use for 25 years, few local products have been 
developed. The 47 companies classified as ‘core’ biotech companies produced about 
155 products and/or services which were applied predominantly in human health, 
support services and plant biotech.  
 
Figure 5: Sectoral distribution of biotech products  
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Source: National Biotech Survey, 2003 
 
The creation of biotechnology RICs is intended to address this gap between research 
and innovation. There are currently three BRICs which specialize in different areas. 
The Biopad RIC of the Gauteng region focuses on animal health and industry and 
environmental related biotechnology. A reported 25 projects are currently being 
funded by the Gauteng Centre.51 The Cape Biotech Initiative (CBI) represents the 
Western Cape region and focuses on human health bioprocessing. The East Coast 
Biotech (Ecobio) serves the Kwa Zulu Natal and the East Coast. This too focuses on 
human health and bioprocessing. Initially, no emphasis was placed on plant 
                                                
50
 Wolson, P. (2001) supra. 
51
 SouthAfrica info (2003) Developing  SA’s Biotech Industry, 10 March 2003 available at 
http://www.southafrica.info/doing_business/trends/newbusiness/biotech.htm  
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biotechnology as can be seen from the allocation of focal areas. It was decided that all 
BRICs will contribute to plant biotechnology although Ecobio will coordinate and 
receive funds for plant biotech. Eventually, this will be phased out over time and as 
funding increases, the other BRICs will also be involved in plant biotechnology.  
 
The formation of the National Bioinformatics Network (NBN) is also central to the 
innovation, commercialization and advancement of biotechnology in South Africa. 
This is based at the University of Western Cape and the University of Pretoria. The 
NBN provides computational power, genome interpretation facilities and networking 
links between the BRICs and other research institutes. The NBN also enhances the 
creation and development of bioinformatics skills and capacities in South Africa. 
 
Other actors in the South Africa biotechnology landscape with activities likely to 
influence commercialization and innovation include the GODISA programme which 
aims at increasing economic growth and employment creation through the 
enhancement of technological innovation, improvement in productivity and 
accelerated international competitiveness of South African small, medium and micro 
Enterprises (SMMEs). The programme supports an Innovation Support Centre, a 
Technology Demonstration Centre, and six Technology Incubators. Plans are 
underway for further funding of more technology incubators. Most of these initiatives 
are in the implementation stages and only a handful have operations spanning three 
years. As such, their impact on commercialisation of biotech remains to be seen. Data 
on this was not available. The initiatives however present a positive outlook for 
commercialisation of biotech in South Africa.  
 
Patenting activity 
 
Generally, scientists in South Africa have favoured publication rather than the 
commercial value of their work; consequently, the level of patent output is low 
compared to other developing and developed countries.52 
  
There were at least 200 biotechnology-related patents filed in the South African 
Patents Office by South African inventors between 1979 and 200253 while 86 biotech 
patent applications by South African inventors were received by the Patent Co-
operation Treaty (PCT) between 1985 and 2003. It is possible that the patent numbers 
reflected do not reflect full complement of IP in South Africa given that ongoing 
research is yet to yield products which can be protected by IP. The substantial filing 
fees may be a deterrent for South African biotech companies, most of which are 
SMEs, from seeking patents abroad. 
 
 
 
                                                
52
 Generally, Cloete, E., L. Nel & J. Theron (2006) ‘Biotechnology in South Africa’. TRENDS in 
Biotechnology  24/12 557-562; Quach, U. et al (2006)’ Biotechnology patenting takes off in developing 
countries’. International Journal of Biotechnology 8, 43-59; and Katnelson, A. (2004) ‘South Africa 
fights low patent rate’. Bioentrepreneur available at http://www.nature.com/bioent last accessed 28 
November 2006 
53
 National Biotech Survey (2003) supra. This notes that the figure is an estimate given that the SA 
patent office does not use International Patent Classification. The estimate figure represents those 
patents which the researchers presumed to be biotech patents from the titles in individual patent 
applications.  
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Figure 6: Number of PCT biotech patents 
 
No. of PCT biotech patents
0
2
4
6
8
10
12
14
16
18
20
1995 1996 1997 1998 1999 2000 2001 2002 2003
 
 
Conclusion 
 
Commercial biotechnology in South Africa is mainly led by Small and Medium sized 
private firms. The government has targeted biotechnology development as a priority 
research area and has increased funding to the sector. However, in spite of over two 
decades of research, there are few local biotech products, and the local biotech sector 
is largely dependent on imported technology. This is reflected in relatively low levels 
of local biotech innovation.  
 
In spite of increased government funding and private investment, the sector suffers 
from insufficient public and private funding for research and commercialisation. The 
newly created regional innovation centres have potential to attract funding although 
their impact remains to be seen.  There is a shortage of suitably skilled technical 
personnel and entrepreneurial and technology transfer skills.   
 
Recent government emphasis on biotech has led to an increase in the number of 
biotech related policy documents, strategies, road maps and plans which define the 
framework under which biotech can develop. It is expected that the new framework 
will rectify the general lack of cohesion in research programmes and address the gap 
between research and commercialisation. 
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5. KENYA 
 
Overview of biotechnology  
 
In most literature, reports and surveys on biotechnology in Kenya, there is virtually no 
mention of biotechnology in other sectors other than in agriculture. There is however 
anecdotal evidence of biotechnology in the health and industrial chemical sectors. As 
such, this report is constrained in its unintentional leanings towards agricultural 
biotechnology rather than biotechnology as a whole.  
 
Plant biotechnology has been in use in Kenya since the 1960s. During the colonial 
period, European farmers through the then Kenya Farmers Association were 
employing biological nitrogen fixation biotechnology for the production of fodder 
legumes and soybean.54 The early 1980s saw a rise in the use of tissue culture in the 
production of citrus plants and pyrethrum under a joint initiative by Kenya 
Agricultural Research Institute (KARI) and the University of Nairobi. In 1990, the 
government established the National Advisory Committee on Biotechnology 
Advances and their Applications which advised that the use of modern biotech in 
Kenya would remain uncertain in the face of inadequate technical and regulatory 
capacity. By 1995, the application of tissue culture in crop improvement was 
commonplace in various public and private sector institutions. However, it was not 
until 2000 that modern biotechnology in crop production was used in Kenya. 
Currently, five transgenic crops are in various stages of the approval process by the 
National Biosafety Committee.  
     
The policy and regulatory framework  
 
Kenya lacks a specific policy on biotechnology. Issues relating to biotechnology and 
biosafety have generally been addressed in the national science and technology 
policy. Biotechnology R&D is therefore evolving in a policy vacuum.  
 
Policy makers have in the past made ad-hoc policy related statements on 
biotechnology. This has led to fragmentation and poor communication of the 
biotechnology R&D agenda among various stakeholders. For example, most of the 
biotech initiatives reflect interests of concerned individuals and particular institutions. 
There is little inter-organizational interactions and modern biotechnology activities 
are influenced by institutional preferences and donor funding and are not necessarily 
guided by or aligned to national priorities.55  
 
There is lack of national priority setting and political will to implement biosafety. 
This reflects a lack of awareness of biotechnology and its impact at all levels of 
society beginning with policy makers.56 The National Council for Science and 
Technology (NCST) is charged with the regulation of biotech and has drafted a 
national biotechnology policy which awaits adoption. The draft policy arises out of 
                                                
54
 Odame, H., P. Kameri-Mbote & D. Wafula (2003) ‘Governing modern agricultural biotechnology in 
Kenya: implications for food security’, IDS Paper 
55
 Anyango, B. and P. Shiundu (1999) ‘Institutional arrangements towards biotechnology policy 
making in Kenya’. Paper presented for Biotechnology and Public Policy Training Course, ACTS, 
Nairobi, Kenya.  
56
 This was the resounding view of most of the people interviewed. 
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the recognition that there is need for a national biotechnology policy and framework 
to address all aspects of biotechnology.  
 
The policy has a wide scope which extends to public awareness, legal framework, 
intellectual property issues, capacity for biotech R&D, institutional framework to 
coordinate biotech efforts, funding, safety issues and protection of indigenous 
resources and knowledge.  
 
In 1998, the National Council for Science and Technology (NCST) developed 
guidelines for biosafety in biotechnology. The NCST through the National Biosafety 
Committee (NBC) is the coordinating office on all issues related to biosafety. The 
1998 Regulations and Guidelines lack an enabling statute. While non-legislative 
means such as a ministerial decree are faster and simpler to issue and are more readily 
amended or replaced, there are enforcement constraints. Without an enabling statute, 
the guidelines may lack substance. It is for example legally difficult to prosecute one 
who contravenes the guidelines as they lack the weight and enforcement power of 
government regulatory authorities. A draft Biotechnology Development and Biosafety 
Bill is currently in parliament awaiting debate. The bill establishes the National 
Biosafety Board whose functions include formulating and implementing policies, 
plans and programmes for the development of biosafety in Kenya; overseeing the 
formulation of standard provisions governing rights and obligations of biosafety 
institutions; promoting efficiency in the development of biosafety through the 
establishment of appropriate institutional linkages and promoting and encouraging the 
use of environmentally friendly technologies. 
 
The current Regulations and Guidelines cover research on recombinant DNA, 
categorized experiments, plant biosafety, quarantine procedures, containment and 
field experimentation. Other areas such as the deliberate release of GMOs, the 
importation of biotechnology products and sanctions to ensure compliance with 
biosafety measures are also addressed.  
 
The regulations describe the steps to be followed to develop a national biosafety 
system. The NCST was designated by the government as the authority to oversee the 
coordination and implementation of biosafety Regulations and Guidelines. Its 
secretariat, the inter-agency NBC, draws up policies and procedures and vets research 
applications to ensure responsible application of biotechnology in Kenya. The NBC 
has been operational since 1998. 
 
Research activity  
 
Although Kenya seems to have a comparative advantage in biotechnology due to 
great genetic diversity and a significant scientific base borne out of institutions that 
have a long tradition in research, there does not seem to be much emphasis placed on 
actual investment in new and innovative ways of tapping benefits from biotechnology 
or in biotechnology research and development.  
 
Kenya has a well established system of national research in agriculture as well as in 
health. This is characterized by public goods research, use of conventional 
technology, and centralized and hierarchical organization. The institutions in this 
national system include national research institutes, academic institutions, NGOs, 
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producer associations and other community based organizations. The Kenya Medical 
Research Institute (KEMRI) is the lead institute in health biotech while in  plant 
biotechnology, the actors include the national agricultural research institute i.e. the 
Kenya Agricultural Research Institute (KARI), universities and international 
agricultural research institutes (IARCs). Private sector engagement in agricultural 
biotechnology is taking root in Kenya. However, it is mainly multinational companies 
that are involved. Although there is some level of collaboration between these groups, 
there has not been full exploitation of organizational synergies.  
 
In the health centre, the Centre for Biotechnology and Research Development within 
KEMRI is mandated to develop biotech innovations especially diagnostic tools, 
vaccines and biological materials. Current areas of research include HIV/AIDs and 
malaria among others.57 Anecdotal data shows that medical biotech is also conducted 
in the department of medicine in Moi University and at the University of Nairobi. 
Data showing the extent of experimentation is however not available. 
 
Human resource development  
 
Kenya has built capacity over the years in traditional biotechnology.  In plant biotech, 
there are numerous projects involving tissue culture and marker assisted technology 
most of which are being conducted under KARI and institutions such as universities.58  
 
Capacity for molecular biotechnology and risk assessment is however lacking in 
Kenya as in most African countries. Although the majority of scientists in Kenya have 
basic scientific knowledge in genetics and molecular biology, they lack practical 
experience to effectively apply their existing knowledge to modern biotechnology.59 
KEMRI has contributed to health research capacity through various initiatives. These 
are however not solely targeted to biotech but to health in general. Data on 
approximate number of researchers working in biotechnology is not available.  
 
The capacity of scientists is underutilized where there is lack of or low funding to 
provide for research grants and staff salaries. Retaining of qualified personnel is also 
at risk as the few highly trained scientists leave the country for better career 
prospects.60  
 
The government and research institutions in Kenya do not have specific training 
strategies for building national capacity in biotechnology. There are however biotech 
related degree programmes at three universities. The Jomo Kenyatta University of 
Agriculture and Technology offers various programmes on agriculture while medical 
biotech courses are available at Moi University and University of Nairobi. Further 
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data on the breakdown of the biotech related courses and the number of enrolled 
students is not available.  
 
Research institutions have incorporated their training needs within the framework of 
individual research programmes.61 There are insufficient knowledgeable and trained 
policy makers. Think tanks such as the African Centre for Technology Studies 
(ACTS) and other policy international and national NGOs have been instrumental in 
organising training and workshops to raise awareness in biotech among policy makers 
and researchers. Capacity is lacking in biotech R&D and in auxiliary fields such as 
intellectual property rights. 
 
Funding  
 
There is limited and contradicting data on level of funding in biotechnology. What is 
apparent is that research in biotechnology - mainly agriculture and health - is public 
sector led with the few private sector companies involved being multinationals. A 
significant proportion of funding comes from bilateral donors and is of a short-term 
nature. Government funding for biotechnology has remained minimal; research 
institutions recognise the need to explore alternative long-term financing for biotech. 
There is lack of appropriate policies, laws and institutional arrangements to support 
innovative alternatives such as venture capital. 
 
It is worth noting that virtually all experimentation in agriculture and health 
biotechnology involving private companies occurs in partnership with government 
institutions. There is therefore an emerging pattern of public private partnerships.  
 
Resources such as appropriate facilities and equipment to conduct biotechnology need 
upgrading in Kenya. This requires financial resources at a time when public research 
is faced with dwindling funds. It appears that lack of funding in addition to relevant 
trained personnel are acute and serious constraints for laboratory capacity in Kenya. 
 
In additional to these implementation drawbacks, other constraints include poor 
linkages and networks. There is lack of adequate collaborative arrangements amongst 
researchers and research institutions. Biotechnology requires a multi-disciplinary 
collaboration between researchers, lawyers, engineers, information technology 
experts, market researchers, business experts and other professionals. Poor 
infrastructure poses another problem; biotechnology heavily relies on knowledge 
flows. Poor information technology - manifested in underdeveloped modern 
communication systems, access to email and internet- impedes the acquisition and 
exchange of necessary and relevant information vital in biotechnology. 
 
Research output: patents 
 
The Kenya Industrial Property Institute (KIPI) is charged with the administration of 
patents. KIPI does not use the International Patent Classification and therefore it is 
difficult to know what share of the total patents belongs to biotech. Since its inception 
in 1991, KIPI has received about 450 patent applications from local and foreign 
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 Odame et al (2000) supra.  
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applicants. There have been about 330 PCT applications and over 3000 applications 
through the African Regional Intellectual Property Organisation (ARIPO).62 
 
Conclusion 
 
Kenya is far from being a hotbed of biotechnological invention. Government 
commitment to biotechnology has not been clearly expressed: there has been no 
budgetary commitment to biotech R&D and the draft Biotechnology bill and 
biotechnology policy have been in and out of parliament since 2003. There is virtually 
no commercialisation of biotech products. Insect resistant maize developed by KARI, 
the International Research Centre for Maize and Wheat (CIMMYT) and Syngenta 
Foundation will be the first product of modern plant biotech to be commercialised in 
Kenya.63 
 
Although skilled scientists exist in traditional forms of biotechnology, modern biotech 
suffers from limited capacity in research scientists. So while there is limited capacity to 
use second generation biotechnologies, Kenya depends heavily on foreign organisations 
such as corporations and development agencies for technology transfer, technical 
support and funding. The private sector in Kenya spends virtually nothing on agro-
biotechnology research, and is not a user of genetic engineering techniques except for 
tissue culture, a situation that has not changed at all since the passage of the Industrial 
Property Act. Public sector research institutes and continues to contribute almost all of 
total research expenditure. And much of the total research funding is provided by foreign 
aid donors. Lack of funds has resulted in limited infrastructure with facilities like 
testing equipment, laboratories, machinery, etc in dire need of an upgrade. 
 
While the ability of Kenyan firms to copy biotech inventions by reading foreign patent 
specifications may be quite limited, even this possibility is precluded when the same 
inventions are patented in Kenya. Therefore, allowing foreign corporations to acquire 
patents in Kenya arguably only increases dependency without any apparent mitigating 
benefits. 
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 KIPI (2005) personal communication. 
63
 Wachai, J. (2006) ‘Kenya inches closer to food sustainability’, Africabiotech 11 November, available 
at http://www.africabiotech.com/news2/article.php?uid=151 
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6. INDIA 
 
Institutional framework 
 
The Indian biotech institutional framework can be traced back to the 1940s with the 
establishment of the Council for Scientific and Industrial Research (CSIR). This is a 
government institute with a network of about 40 laboratories, 80 field stations and 
which employs over 22,000 personnel.64  Of the 40 laboratories, at least seven engage 
in biotech research. These are the Centre for Biochemical Technology (CBT) in 
Delhi, the Centre for Cellular and Molecular Biology (CCMB) in Hyderabad,65 the 
Indian Institute of Chemical Technology (IICT) in Hyderabad, the Central Drug 
Research Institute (CDRI) in Lucknow, the Institute of Microbial Technology (IMT) 
in Chandigarh, the Indian Institute of Chemical Biology (IICB) in Calcutta and the 
Central Food Technological Research Institute (CFTRI) in Mysore.66 
 
The institutional framework was further bolstered in the 1980s: the Sixth five-year 
Plan (1980-1985) was India’s first policy document covering biotechnology 
development.67 CSIR was mandated to ensure co-ordination on an inter-agency, inter-
institutional basis. One of the most important boosts to biotechnology development 
was the establishment of the National Biotechnology Board (NBTB) in 1982 to 
spearhead the development of biotech. Its primary objective was to identify priority 
areas in biotech development and to devise a long term plan for biotech in India. In 
1983, NBTB issued the ‘Long Term Plan in Biotechnology in India’ which identified 
as priority areas self sufficiency in food, clothing and housing, adequate health and 
hygiene, provision of adequate energy and transportation, protection of the 
environment, employment, industrial growth and balance in international trade. The 
NBTB graduated to the Department of Biotechnology (DBT) in 1986. Its mandate is 
to promote biotechnology throughout India.    
 
At present there are seven major agencies concerned with financing and supporting 
research in biotechnology. These are the Department of Science and Technology 
(DST), the Department of Biotechnology (DBT), the Council of Scientific and 
Industrial Research (CSIR), the Indian Council of Medical Research (ICMR), the 
Indian Council of Agriculture Research (ICAR), the University Grants Commission 
(UGC) and the Department of Scientific and Industrial Research (DSIR). These 
agencies are spread over four different government departments.68 
 
 
 
 
                                                
64
 Ernst & Young (2002) Biotechnology in India.  
65
 This was established in 1977 solely for the advancement of biotechnology. 
66
 Maria, A., J. Ruet, J. & M.-H. Zerah (2002) Biotechnology in India. A study commissioned by the 
French Embassy in India (hereafter French Embassy Report).  
67
 Bhargava, P. (1995) ‘Biotechnology’s decade of stagnation’. Economic and Political Weekly, vol. 
30/48 
68
 DST, DBT and DSIR are under the Ministry of Science and Technology; ICMR is under the 
Ministry of Health, ICAR is under the Ministry of Agriculture, UGC under the Ministry of Human 
Resource Development. DSIR is the funding agency for CSIR and both fund biotech related research 
projects.  
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Table 1: Budget allocations of major biotechnology funding agencies (millions of 
US$)  
 
 1990/91 2000/01 2002/03 2003/04 2004/05 
Indian Council of Agriculture 
Research (ICAR) 
 
667 
 
1647 
 
1667 
 
1615 
 
1934 
University Grants Commission 
(UGC) 
 
720 
 
1656 
 
1774 
 
1749 
 
1832 
Dept of Scientific and 
Industrial Research (DSIR) 
 
511 
 
1142 
 
1180 
 
1219 
 
1439 
Dept of Science and 
Technology (DST) 
 
533 
 
918 
 
1150 
 
1262 
 
1420 
Council of Scientific and 
Industrial Research (CSIR) 
 
484 
 
1073 
 
1145 
 
1184 
 
1399 
Dept of Biotechnology (DBT)  
135 
 
160 
 
267 
 
293 
 
358 
Indian Council of Medical 
Research (ICMR) 
 
82 
 
173 
 
185 
 
179 
 
197 
TOTAL 3133 6768 7368 7501 8579 
Source: Chaturvedi, 2005 
 
Research activity  
 
In the 1980s, programmes on biotechnology included tissue culture application for 
medicinal and economic plants, fermentation technology, enzyme engineering for 
chemicals, antibiotics  and other medical product development, agricultural and forest 
residues and slaughterhouse wastes utilisation.69 In addition to these first and second 
generation biotech activities, India’s engagement in third generation biotech activities 
such as  pharmaceuticals, plant and animal biotech, aquaculture and marine biotech, 
and environmental biotech has grown strongly over the past two decades. With 
India’s growing global prominence in information and communications technology, 
bioinformatics as a sector in biotech is growing rapidly. DBT reports that it received 
1325 project proposals in 2005-2006 period 805 of which were recommended for 
funding.70   
 
A study conducted by Ernst and Young in 2000 found that there were 800 biotech 
companies.71 15 percent of these engaged in third generation biotechnology. The 
study found that the biotech industry at the time employed about 10,000 technical 
staff and generated about USD 500million in revenue per annum.  
 
Similar studies conducted by the Biotech Consortium India Limited (BCIL) in 2001 
and 2003 however display more conservative figures highlighting the problem of 
discrepancies in the biotech data available. The 2001 survey lists 176 biotech firms 
while the 2003 survey lists 401 firms.72  With 85 firms, agriculture was the largest 
                                                
69
 Planning Commission (1981) India, Sixth Five Year Plan Document, 1980-1985, Government of 
India, New Delhi. 
70
 DBT Report, 2006. Available at http://dbtindia.nic.in/publication/publicmain.html  
71
 This includes companies engaging in first generation biotech.  
72
 Only about 25% of firms are common to both surveys. While this indicates that there is a high 
number of new firms, there is however no explanation on missing firms. See Chaturvedi, S. (2005) 
‘Dynamics of biotechnology research and industry in India: Statistics, perspectives and key policy 
issues’, DSTI/DOC(2005)6 for an analysis of the problem of contrasting data.  
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biotech sector in 2001 representing 48% of the total. Healthcare came second with 
about 24% of the total. With its 43 firms increasing to 142 firms in 2003, healthcare 
was the largest sector in 2003 having a share of 35% compared to agriculture’s 33%. 
Firms engaging in environmental biotech increased from 4 to 16 while 2003 figures 
indicate a sector not present in 2001: industrial biotechnology. These are mostly firms 
engaging in extraction related activities and at 42 firms represented 10% of the total 
biotech firms in 2003.  
 
Table 2: Sectoral breakdown of biotech firms in India, 2001 and 2003 
 
 2001 2003 
 Number Share of total (%) Number Share of total (%) 
Agriculture 85 48.3 132 32.9 
Healthcare 43 24.4 142 35.4 
Environment 4 2.3 16 4 
Industrial Biotech - - 42 10.5 
Others 44 25 69 17.2 
TOTAL 176  401  
Source: BCIL 2001, BCIL 2003 
 
Most biotech firms in India are private and are predominantly small. Only about 12 
biotech firms are listed on the capital market. BCIL data shows that the share of small 
firms remained constant at about 60% in 2001 and 2003. The number of large firms 
decreased from a share of 25% to 40% in 2003 while that of medium sized firms 
increased from 13% to about 20%. There is a significant number of US and European 
multinationals with a manufacturing presence in India.73 
 
Contract Research Organisations74 have largely been responsible for the rise in the 
absolute number of small firms in the healthcare sector from 10 in 2001 to 74 in 2003 
representing the largest percentage increase across the sectors over the period. In 
agriculture and healthcare, medium sized firms have increased at the same pace. In 
the healthcare sector, large firms have increased by about 80% suggesting a rapid 
entry of multinational companies.   
 
Table 3: Number of biotech firms by size and sector 2001  and 2003 
 
 Agriculture Environment Healthcare Industrial Others Total 
 2001 2003 2001 2003 2001 2003 2001 2003 2001 2003 2001 2003 
Small firms (<51 
employees) 
 
63 
 
87 
 
4 
 
9 
 
10 
 
74 
 
- 
 
39 
 
30 
 
31 
 
107 
 
240 
 
Medium firms 
(51-150 
employees) 
 
10 
 
26 
 
- 
 
1 
 
8 
 
21 
 
- 
 
15 
 
6 
 
15 
 
24 
 
78 
 
 
Large firms 
(>150 employees) 
 
12 
 
14 
 
- 
 
4 
 
25 
 
45 
 
- 
 
10 
 
8 
 
10 
 
45 
 
83 
Total no. of firms  
85 
 
132 
 
4 
 
16 
 
43 
 
142 
 
- 
 
42 
 
44 
 
69 
 
176 
 
401 
Source: BCIL 2001, 2003 and Chaturvedi, 2005 
 
                                                
73
 For example GlaxoSmithKline, Eli Lily in health and Monsanto and US Agriseeds in agriculture. 
74
 Chaturvedi, S. (2005) supra.  
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Bioinformatics as a biotech sector is growing rapidly on the back of India’s strong IT 
sector. The government has had a large part to play in the growth of this sector partly 
by enhancing the equity of foreign companies and institutions in government funded 
research centres to 51%.75 In addition, a network of at least 57 research centres linked 
to a high speed computer network Biotechnology Information Systems Network 
(BTISnet) has been established.76 Some state governments have also initiated efforts 
at strengthening bio-nanotechnology and plant genomics.  
 
A significant proposition of biotech firms is concentrated in Central and Southern 
India. The 2002 French Embassy survey identified 18 main public research 
institutions 10 of which are in Central and Southern India. Hyderabad in Andra 
Pradesh in the south stands out with about 40 research institutes solely dedicated to 
biotech. Other prominent states include Karnataka, Tamil Nadu and Kerala. The 
western state of Maharashtra has large biotech centre whose base expands to other 
states such as Gujarat and Chandigarh.   
 
Funding 
 
Biotechnology is highly dependent of the availability of funds at initial stages of 
R&D. Access to capital for biotech firms is through government funding or private 
venture capital. Government support is typically targeted at government institutions 
and research agencies. There is little government support for private sector R&D 
outside of that available from the Technology Development Fund which finances 
CSIR-approved projects. However, some state governments have set up biotech 
development funds to assist private companies engaging in biotech.  
 
In the 2005-2006 period, the biotech industry registered a revenue of USD 1.07billion 
recording a growth of 36.55%.77 Leading public agencies supporting biotechnology 
programmes include the Indian Council of Agriculture Research (ICAR), the 
University Grants Commission (UGC), the Department of Scientific and Industrial 
Research (DSIR), the Department of Science and Technology (DST), Council of 
Scientific and Industrial Research (CSIR), Department of Biotechnology (DBT) and 
the Indian Council of Medical Research (ICMR). It should however be noted that 
apart from DBT which deals solely in biotech, it is difficult to establish the share of 
funding allocated to biotech in the agencies as allocations are not separately marked 
for biotech.  
 
The national budget Table 1 above is a broad overview of the total allocations in the 
above mentioned agencies. Apart from ICMR, DBT has registered modest growth 
relative to the other agencies. This may perhaps be indicative of its role of 
coordination of nationwide biotech research rather than direct R&D.  
 
The national budget for the 2001-2002 fiscal year gave biotech firms a 150% tax 
deduction for R&D in a move aimed at encouraging private sector investment in 
biotech. The government also promotes the establishment of biotech centres within 
industrial parks. The Andhra Pradesh state in collaboration with the private sector has 
                                                
75
 Suresh, N. (2003) ‘Bioinformatics policy calls for 51% FDI in government labs’, 17 March 2003. 
Available at http://www.ciol.com/content/news/repts/103031701.asp 
76
 Chaturvedi supra.  
77
 DBT Report 2006 supra. 
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built a state-of-the-art biotech park in Hyderabad. This is intended to be replicated in 
other states. Some of these projects are partly funded by the central and state 
governments as well as private investors. 
 
Other measures to promote private sector investment and innovation include the 
establishment of the Small Business Innovation Research Initiative (SBIRI), a scheme 
launched for funding early stage pre-proof of concept research. Plans to expand this to 
fund projects which have established proof of concept and have the ability to get 
venture capital are underway.78 
 
Private sector investment in 2002 amounted to USD10.6billion up from 3.1 in 1999.79 
The health and medical sector accounted for 47% of the total while agriculture 
received 32%.  
 
Table 4: Private sector investment in biotech 1999 and 2002 (US$ m) 
 
 1999 2002 
Health 2118 5024 
Agriculture   900 3350 
Industrial biotech -   635 
Environment        3   253 
Others   101 1354 
TOTAL 3122 10616 
Source: BCIL 2001, 2003 and Chaturvedi 2005 
 
Venture capital 
 
The number of venture capital firms in India has increased greatly since 1988 when 
the government announced the guidelines for setting up venture capital funds. The 
restriction that venture capital funds could only be set up by banks and financial 
institutions was removed in 1995 allowing for tax exemption therefore encouraging 
capital investments from overseas.. The Venture Capital Funds Regulations were 
promulgated in 1996; at the time, only 8 domestic venture capital funds were 
registered. In 2004, the number of funds had increased to at least 70 with USD29 
billion in assets under management.  
 
There are limitations in data collection with regard to the share of funds available to 
biotech. However, the data available seems to suggest that venture capital currently 
plays only a marginal role in funding biotech. In the French Embassy study, only 4 
companies of the 41 interviewed received support through venture capital funds.  
 
Interestingly, venture capital in India is dominated by public sector financial 
institutions the largest of which are Industrial Credit and Investment Corporation of 
India (ICICI) and Small Industries Development Bank of India (SIDBI). ICICI and 
the Andra Pradesh Industrial Development Corporation are the leading biotech funds. 
Other funds include IL&FS Venture Corporation Ltd., Industrial Development Bank 
of India (IDBI), and the Industrial Finance Corporation of India (IFCI). There are 
                                                
78
 This will be in the form of soft loan for up to Rs. 10 Crores. DBT Report (2006).  
79
 Meaning the total sum of investments made by companies in the biotech industry. 
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several other financial agencies with limited funds earmarked for biotech. Morgan 
Stanley is a private venture capital fund that has been active in funding biotech. 
However, most venture capital funds have been unwilling to invest in biotech R&D 
opting rather to fund commercialisation of research already developed.80  
 
Human resource development 
 
There have been various efforts by the government to build capacity in biotech. In 
1984, NBTB launched short term training programmes to address rising demand for 
trained personnel in biotech. DBT promotes the development of specialised degrees at 
various universities at both MSc and PhD level. There are about 50 approved training 
programmes in various institutions.81 In addition, there are over 60 institutions set up 
by the private sector offering degrees and diplomas in biotech.82 Technician training 
courses, fellowships for students to go abroad, overseas associateships for qualified 
scientists, lecture series, awards and incentives form an integral part of human 
resource development in biotech in India.83  
 
Table 5: Training in biotech 2003-2004 
 
 No. of 
institutions 
6mnths – 1yr 
programmes 
2 - 3yr 
programmes 
PhD 
Msc. Gen Biotech 30  413  
MSc. Agriculture 7  80  
Master in Medical biotech  
1 
  
10 
 
MSc. Marine 2  30  
MSc. Neurosciences 3  25  
MSc. Industrial biotech 1  10  
MSc. Biochemical 
engineering & biotech 
 
6 
  110 
MSc. Pharmaceutical 1  10  
Post MD./ MSc. Cert in 
medical biotech 
 
2 
 
9 
  
PGD genetic engineering 
& bioprocess development 
 
1 
 
 
12 
  
PGD molecular biotech 1 20   
Postdoc course from DBT  
3 
   
Source: DBT report, 2004 
 
In 2003, there was about 160,000 people employed in biotech 39,000 of whom were 
technical staff.84 Healthcare had the largest share of employees in 2001 (47%) and in 
2003 (53.2%). The share of technical staff in agriculture remained constant at 30.8% 
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 E&Y Report (2002) supra.  
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 DBT report (2006) supra. 
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 Chaturvedi, S. (2005) supra, but no data available. 
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 Awards include the competitive National Bioscience Career Development Awards. There are also 
special programmes to increase participation of women in science such as the Biotechnology Golden 
Jubilee Park for Women encouraging women entrepreneurs to take up biotech enterprises.  
84
 BCIL (2003) Directory of Biotechnology Industries and Institutions in India, BCIL, New Delhi. 
More recent figures are not available. 
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in 2001 and 31.3% in 2003. Although this greatly increased from 18.1% to 30.6% in 
healthcare, agriculture had a greater share of technical staff in both years. Industrial 
biotech and environmental biotech each accounted for about 9% of technical staff in 
2003. 
 
Table 6: Number of employees in biotech 2001, 2003 
 
 2001 2003 
 Total % Technical % Total % Technical % 
Agriculture 15029 24.8 5217 30.8 32623 20.3 12206 31.3 
Healthcare 28520 47.1 3066 18.1 85600 53.2 11948 30.6 
Environment       66 0.1     30 0.2   6136 3.8    3295 8.5 
Industrial -* -* -* -* 14514 9.0    3335 8.6 
Others 16905 27.9   8619 50.9 22026 13.7    8228 21.1 
TOTAL 60520  16932  160899  39012  
* data unavailable 
Source: BCIL 2001, 2003 
 
Synergies and partnerships 
 
The BCIL was set up in 1990 with the aim of providing linkages among research 
institutions. Its budget comes from various Indian financial institutions as well as 
private firms. There have been various initiatives aimed at promoting collaboration 
between various institutions and agencies in the private and public sector some of 
which are promoted by state governments such as the establishment of biotech parks 
in Andhra Pradesh,85 Uttar Pradesh and Karnataka. BT parks offer the infrastructure 
to facilitate experimentation as well as placing biotech firms in one location thereby 
creating opportunity to share not only resources but also knowledge culminating in 
partnerships and collaborations. 
 
Some outstanding examples include CCMB’s work with the private sector to develop 
India’s first recombinant DNA vaccine for Hepatitis B.86 Typically, private firms 
partner with CCMB by funding a particular project; CCMB does the R&D and the 
private sector partner handles commercialisation. Other collaborations are between 
multinational subsidiaries and local companies such as an agreement between Eli Lily 
and Ranbaxy to market Monsanto’s recombinant bovine growth hormone. Of 50 
Indian private companies interviewed, there were 53 interactions involving 19 private 
companies and 27 public institutes. 13 companies had interactions with more than one 
public institute.87  
 
In bioinformatics, the US accounts for about 65% of India’s IT exports.88 Indian 
companies are looking to leverage data mining and data warehousing with some 
                                                
85
 The SP Biotech Park is a joint venture between Shapoorji Pallonji & Co. Ltd. and the Andhra 
Pradesh government. The latter contributed 140 acres of land and owns 11% of the shares. There is also 
a Knowledge Park in Hyderabad, a joint venture between the state government and ICICI. It sits on 200 
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larger blue print of the Genome Valley Project 
86
 With Shantha Biotechnics Ltd in Hyderabad, E&Y Report 
87
 French Embassy Study, supra. 
88
 Ernst & Young (2002) supra. 
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considering establishing subsidiaries abroad and using these to nurture business 
relationships.89  
 
Administration and legislative policy 
 
Diversity of agencies characterise regulation of biotech in India; regulation is spread 
through four ministries - Health, Agriculture, Science and Technology and Human 
Resource and Development – and over eight agencies within the ministries.  
 
The Indian Patent Act of 1970 as amended does not define ‘micro-organism’ and does 
not allow for patenting of plant or animal varieties; it however allows for the 
patenting of biotech processes. India established biosafety guidelines in 1989 and has 
Biosafety and Recombinant DNA Guidelines (1990) which fall under the 
Environment (Protection) Act of 1986. The Guidelines for Biomedical Research were 
drawn up in 2000.  
 
India does not have a national biotechnology policy but some state governments such 
as Maharashtra, Andra Pradesh, Karnataka, Tamil Nadu and Gujarat have developed 
biotech policies at state level and established specific institutions to oversee biotech 
within the respective states.90 The central government is in the process of developing 
a national 10year strategy and action plan which is currently in draft form. The draft 
biotech strategy broadly reflects that in the IT industry 
 
Output 
 
The biotech industry generated USD 1.07 billion in the 2005-2006 fiscal year 
recording a growth of 36.55%.91 The number of scientific articles by Indian scientists 
rose significantly in the same period.92  
 
The Technology Information Forecasting and Assessment Council (TIFAC), the 
National Research Development Corporation and the various patent offices are 
charged with the responsibility of managing patent data. None of these uses 
International Patent Classification therefore, while there is data available on overall 
number of patents applied for and granted, it is difficult to establish which of those 
relate to biotech. This notwithstanding, Figures from TIFAC estimate that there were 
about 2300 biotech patent applications filed in India.  
 
 
                                                
89
 Perhaps following the example set by Dr. Reddy’s Lab which is listed on the New York Stock 
Exchange.  
90
 Some state governments have gone further to encourage innovation in biotech. In Andhra Pradesh, 
companies enjoy a sales tax of only 1% on biotech products produced within the state. 
91
 DBT Report 2006 supra.  
92
 Ibid. There was also an increase in the number of publications by DBT’s autonomous institutions.  
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Figure 1: No. of biotech patents filed in India 1995 – 2002 
Number of biotech patents filed in India, 1995-
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Source: TIFAC, 2003 
 
Conclusion  
 
Framework and strategy for regulating biotech in India borrows heavily from that in 
the IT sector. The biotech sector faces difficulty owing to the complex nature of 
administration. State efforts are not coordinated as states compete with each other to 
become the most attractive location for biotech investment. Nevertheless, there are 
efforts aimed at streamlining the institutional environment. There is considerable 
investment in academic and industry infrastructure as well as human resource 
development resulting in an impressive national network of research institutions with 
immense potential for growth.  
 
Innovation in biotech in India ranges from highly intensive R&D such as the Relicord, 
a product of human stem cell research developed by Reliance Life Sciences93  to 
creative imitation which forms the basis of the Indian pharmaceutical industry. India 
is both one of the largest market for generic drugs and its pharmaceutical industry is 
the world’s largest exporter of generic drugs, a role soon to change given recent 
amendments of the Indian Patent Act to conform to TRIPS requirements. 
 
The difficulty in biotech data collection and the disparity in the data available make 
comprehensive analysis of the biotech environment difficult. Various studies have 
attempted to address this with limited success. There is no common definition of 
biotechnology which means that the scope of companies from which biotech data is 
obtained differs across various studies.   
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 Reliance Life Sciences (2006) Stem Cell Enriched Cord Blood Repository. Available at 
http://www.relbio.com/html/sc_bloodrepository.html 
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7. ANALYTICAL PRESENTATION OF THE FLEXIBILITIES OF TRIPS 
ARTICLE 27.3(b) 
 
As indicated earlier, two types of flexibility exist in Article 27.3(b). These are (i) the 
optional subject matter exceptions, and (ii) the possibility to define the terms in a 
variety of ways. This part of the report discusses the potential interpretations of 
Article 27.3(b) of the TRIPS Agreement and their implications for the development of 
biotechnology. In order to do so the following approach is adopted. An overview of 
the TRIPS Agreement and Article 27.3(b) addresses the possible interpretations by 
identifying flexibilities or ambiguities based on the architecture of the article as such, 
an analysis of the terms under the scientific language, the various legal interpretations 
and their practical industrial or technological implications. It lays out the various 
stakes of such article, the reasoning behind the wording, and the precise and practical 
understanding of the terms.  
 
To illustrate the flexibilities empirically, we also review the way WTO Member 
States have implemented and applied the wording of Article 27.3(b) in their national 
law, repeating how terms are interpreted in those implementations. But we start with 
Article 27.1. 
 
Article 27 of TRIPS 
 
Under Article 27.1 of TRIPS, a list of requirements is set that clarifies what type of 
innovation ought to be eligible for patent protection:  
 
[…] patents shall be available for any inventions, whether products or 
processes, in all fields of technology, provided that they are new, involve an 
inventive step and are capable of industrial application. 
 
The implications of Article 27.1 are that, in the context of the application of the 
TRIPS, Member States shall ensure that a patent regime is available to protect any 
inventions that fulfil those requirements irrespective of the technology. Thus, under 
TRIPS, Member States shall not discriminate as to the nature of the technology when 
assessing patentability.  
 
Whereas any inventions that meet the requirements set under Article 27.1 of TRIPS 
must be capable of being protected under a patent regime, Article 27 also 
distinguishes exceptions where this may not be compulsory. Articles 27.2 and 27.3 of 
TRIPS identify restrictions that, even when the requirements for patentable inventions 
are met, allow the State to exclude certain subject matter by integrating other stakes. 
Again, the implementations of those exemptions are not compulsory but left to the 
discretion of each Member State. There are two types of potential exclusions; the first 
one characterizes an unwanted effect of applying exclusive commercial rights over 
certain subject matter, without qualifying which subject matter is susceptible of being 
excluded. 
 
[…] the prevention within their territory of the commercial exploitation of 
which is necessary to protect ordre public or morality. Art. 27.2  
 
The second ones specifically exclude certain subject matter: 
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[…] diagnostic, therapeutic and surgical methods for the treatment of humans 
or animals. Art. 27.3(a) 
 
Or, and precisely at stake within that report: 
 
[…] plants and animals other than micro-organisms, and essentially biological 
processes for the production of plants or animals other than non-biological and 
microbiological processes. However, Members shall provide for the protection 
of plant varieties either by patents or by an effective sui generis system or by 
any combination thereof. Art. 27.3(b) 
 
Article 27.3(b) 
 
Article 27.3(b) starts with the following wording: ‘Members may also exclude from 
patentability’. Again, the TRIPS Agreement does not require or exclude de facto the 
protection of those subject matters, an issue left at the discretion of each Member 
State. The construction of article 27.3(b) can be divided into two parts: 
 
First, the provision ‘[…] plants and animals other than micro-organisms’ specifies 
that plants and animals can be excluded as product patents, but such exclusion cannot 
be extended to microorganisms. Following Article 27.1 TRIPS, it is then required that 
micro-organisms and any macro-organisms other than plants or animals be patentable 
subject matter. In addition, at the end of the article is specified that: ‘Members shall 
provide for the protection of plant varieties either by patents or by an effective 
sui generis system or by any combination thereof’. Hence, even though Member 
States do not have to protect plants under their patent regime, plant varieties have to 
be protected. This can be achieved either under a separate regime held as ‘effective’ 
or within the patent law, or by a combination of both.  
 
The second part of the provision addresses issues of process patents, ‘essentially 
biological processes for the production of plants or animals other than non-biological 
and microbiological processes’. The construction there is more ambiguous. What are 
potentially excludable from patent protection are essentially biological processes, the 
definition of which could be understood by the end of the provision, ‘other than non-
biological and microbiological processes’ that leads to the production of plants or 
animals, and only. Therefore, it can first be understood that non-biological and 
microbiological processes that lead to the production of plants and animals ought to 
be capable of being protected. Moreover, it is only when the purpose is for the 
production of plants and animals, that essentially biological processes can be 
excluded. Therefore an essentially biological process for the production of anything 
else than plants or animals is required to be capable of patent protection. 
 
Furthermore, the restriction on ‘plants and animals other than micro-organisms’ is not 
being reproduced as the term micro-organism is not being repeated. So, the Member 
States should have discretion whether patent rights could be provided to essentially 
biological processes for the production of plants’ and animals’ micro-organisms, 
should there be any.  
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So it appears that the architecture of Article 27(3)(b) provides a certain level of 
flexibility as to the optional subject matter that is not so explicit and may requires 
further clarification. Mainly, the lack of clarity of Article 27.3(b) is generated by the 
terms and associations used that are open to possible different interpretations, thus 
creating a second level of flexibility of Article 27.3(b), as previously held. 
 
Interpreting the terms of TRIPS 
 
Articles 31 and 32 of the Vienna Convention on the Law of Treaties provide that the 
terms should be interpreted ‘in good faith in accordance with the ordinary meaning to 
be given to the terms of the treaty in their context and in the light of its object and 
purpose’. 
 
What should be understood as the ordinary meaning could be an accepted definition, 
as generally found in dictionary. Meanwhile, such definitions might lack precision 
and create some grey areas. When those areas become positioned over issues of 
importance then the interpretation of the terms will need further investigation. 
 
A further means of interpretation lies in the intention of the parties to the agreement. 
Again, the TRIPS Agreement was enacted in order to increase trade harmonization by 
focusing on standardising IPR amongst its signatory States. Substantive variations in 
the way the terms are being interpreted could have the consequence of 
compartmenting the global market, hence would run counter to the intentions of the 
TRIPS.  
  
As identified by the Vienna Convention, the interpretation should also be made in the 
light of the object and purpose of the Treaty, which identify a third level of 
interpretation. The object and purpose of the TRIPS Agreement are to set minimum 
standards of IPR. In that sense, it is not required that Members include within their 
laws level of protection above the minimum. The effort of harmonization is only 
required to the level of those standards, more extensive protection being left at the 
discretion of the Member.94 Hence, the extent to which interpretation should be made 
by confronting other Members’ law should be restricted within the minimum standard 
identified by the TRIPS. Meanwhile, it is obliged that Members incorporate within 
their laws those minimum standards. In that sense, Article 27.3(b), which is an 
exception, should be construed narrowly.   
 
Finally, it is under the competence of the WTO Dispute Settlement Body to interpret 
TRIPS.95  
 
Interpretations of the terms of Article 27.3(b) of TRIPS 
 
Article 27.3(b) defines boundaries in disclosing subject matter that might be excluded 
while providing restrictions on the interpretation made of such subject matter. Thus, 
whereas the terms might be interpreted alone, their real meaning has to be in 
conjunction with the other terms they are associated with.  
                                                
94
 Leskien, D. and M. Flitner (1997) Intellectual Property Rights and Plant Genetic Resources: Options 
for a Sui Generis System, Issues in Genetic Resources No 6, IPGRI, June 1997. 
95
 Art. 64(1) of TRIPS. 
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Table 1: Biotech patenting in TRIPS: what must be provided and what may not 
be  
MUST PROVIDE MAY EXCLUDE UNMENTIONED 
 
1. Microorganisms 
2. Animals and plants (including 
plant varieties) 
 
7. Genes  
 
3. Microbiological processes 
5. Essentially biological 
processes for the production of 
plants or animals 
 
 
4. Non-biological processes  
 
  
6. Plant varieties (either by 
patents or by an effective 
sui generis system or by any 
combination thereof) 
  
 
1. Microorganisms 
 
Microorganism refers to organisms that are not visible by the naked eye, which should 
be in the range or 10-5 m maximum size.96 The term organism means a complex 
adaptive system of organs that influence each other in such a way that they function 
as a more or less stable whole and have properties of life. Generally, plant cells are in 
the range of 10-4m, 10-5 m for animal cells, 10-6 m for bacteria or archaebacteria, and 
even less for viruses. Thus microorganisms are single cell organisms, which are most 
commonly bacteria or archaebacteria. Viruses are not normally classed as organisms.   
 
As emphasised by the US97 in a communication to the WTO, the Budapest Treaty on 
the International Recognition of the Deposit of Microorganisms does not provide a 
definition for microorganisms; nor does TRIPS or the WIPO Committee of Experts on 
Biotechnological Inventions and Industrial Property. The reason could be found in a 
document prepared jointly by the European Patent Office, the Japanese Patent Office 
and the US Patent and Trademark Office98 that held:  
 
None of the laws administered by any of the Offices contains a formal 
definition of the term ‘micro-organism’. Where definitions are used in either 
classification, definitions or administrative guidelines, the term is defined as a 
non-exclusive list of organisms which are included within the scope of that 
term. As noted by the EPO, it does not seem expedient to introduce such a 
definition as the rapid evolution in the field of microbiology would necessitate 
its frequent updating.  
 
The USA communication then based their definition of microorganisms, if any, as ‘an 
organism not visible to the naked eye, e.g. bacterium or virus’99, which should be 
sufficient in their view to distinguish them from plants and animals.  
                                                
96
 a doubt is generally 10-4 m.  
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 IP/C/W/209 WTO 
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Microbiological Inventions, 1988. 
99
 Oxford Dictionary of Current English. 
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Brazil100 also disputed the necessity to clarify the definition of microorganisms. This 
was motivated by concerns about broad patents on microorganisms, where issues of 
novelty, inventive step and industrial applicability were at stake, as well as potential 
conflict with the Convention on Biological Diversity (CBD). While those two issues 
have real existence and practical implications, they are not as such related to the 
implication of Article 27.3(b). Those are matters of basic requirements for 
patentability and procedures, but not issues of subject matter exclusion as such. In 
addition, Article 27.3(b) is articulated in such a way that it provides the possibility for 
Member States to integrate in their patent regime certain exclusions, rather than 
actually requiring them. Hence, it seems inappropriate for it to serve as a lever against 
those practices. Consequently it appears that the lack of a more specific definition of 
microorganisms under Article 27.3(b) is not problematic as to the identification of the 
subject matter, but as to the consequence of protecting certain type of 
microorganisms. 
 
Brazil’s patent legislation excludes from patentability all or parts of plants and 
animals, except transgenic micro-organisms that satisfy the three requirements of 
patentability. For the purpose of this law, transgenic micro-organisms, except for all 
or part of plants and animals, that express, by means of direct human intervention in 
their genetic composition, a characteristic normally not attainable by the species under 
natural conditions.101 
 
An African Group communication to the WTO102 was divergent. It argued that the 
distinction made did not have any scientific reasoning and its interpretation focused 
on the exclusion of life forms in general.  
 
In Europe and Japan, the term is understood extremely broadly. According to the 
European Patent Office microorganism ‘includes not only bacteria and yeasts, but also 
fungi, algae, protozoa and human, animal and plant cells, i.e. all generally unicellular 
organisms with dimensions beneath the limits of vision which can be propagated and 
manipulated in a laboratory. Plasmids and viruses are also considered to fall under 
this definition.’ Similarly, for the Japan Patent Office microorganism includes ‘yeasts, 
moulds, mushrooms, bacteria, actinomycetes, unicellular algae, viruses, protozoa, 
etc.’ and also ‘undifferentiated animal or plant cells as well as animal or plant tissue 
cultures’. 
 
2. Animals and plants (including plant varieties) 
 
The science of taxonomy has evolved over the ages offering an understanding of the 
linkages within the natural world. While it started with general morphology approach, 
where appearance was the main factor of distinction, more invasive methods based on 
cellular biology and genetics provided a more comprehensive and precise picture of 
the organization of life and its variation.  
 
Until the 1960s, only two kingdoms were usually referred to, namely animals and 
plants. Protozoa103 and bacteria,104 being known at that time, were respectively 
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included in the animal and plant kingdoms. While this distinction mainly opposed 
what is called primary and secondary producers105 and could easily be distinctive of 
plants and animals at macroscopic level, it was too limiting at the microscopic level. 
Indeed, more in depth research on the microscopic world revealed life forms that were 
more differentiated between them than any possible differentiation between plants and 
animals.  In 1959, R. H. Whittaker replaced the two kingdoms with five: Animalia, 
Plantae, Fungi, Protista and Monera. 
 
The progress of modern genetics affected further our perception of nature’s 
organization. Instead of five kingdoms, it is now three domains that are being 
differentiated, within which over a dozen kingdoms have been recognized. The main 
distinction then is not really a matter of size, but is held within the microscopic world. 
The three domains known as Eukarya,106 Eubacteria107 and Archaea,108 are mainly 
distinct by their biochemical capabilities, cell structure, and obviously gene 
sequences. The plant and animal kingdoms are part of the Eukarya.  
 
Two main issues arise from those distinctions; first, plants and animals are only a tiny 
fraction of the living world in term of diversity. Second, the visual distinction 
between micro-organism and macro-organism is not representative of fundamental 
differences or capabilities, i.e. most of the characteristics of life are held within the 
microscopic world.  
 
A general definition of the plant and animal kingdoms would be: 
 
- Plant Kingdom: Members of this kingdom grow out of inorganic material by 
photosynthesis. They lack ability to move around their environment except by 
growing or being transported by wind, water, or external forces. They 
comprise mosses, ferns, woody and non-woody flowering plants. 
- Animal Kingdom: Organisms that ingest food instead of absorbing or 
photosynthesizing it. They also have their own means of locomotion in at least 
one phase of their life cycle. They comprise sponges, worms, insects, fish, 
amphibians, reptiles, birds and mammals.  
 
In a strict scientific interpretation, ‘plants and animals other than micro-organisms’ 
means that only specimens within the plant and animal kingdoms that are visible to 
the eye are potentially excludable from patent protection. Based on the definitions of 
plants and animals provided above and repeating the fact that plant cells are in the 
range of 10-4 m and 10-5 m for animal cells, they can thus not be classed as 
microorganisms. Hence, the restriction within the plants and animals exclusion of 
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104
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microorganisms does not seem to have any scientific relevance, unless one is 
considering a different approach.  
 
If we have to give a meaning to the opposition between plant and animals, and 
microorganisms, apart from the requirement that microorganisms be patentable 
subject matter, such distinction may call for an older interpretation of the meaning of 
those terms. The USPTO includes in their definition of plants other organisms such as 
algae and macro fungi.109 Under a strict definition, such macro-organisms are not part 
of the plant or animal kingdoms.  
 
Another approach to distinguishing between plants and animals, and microorganisms 
may also be considered under the term ‘organism’. Thus, the use of the term 
‘microorganism’ in opposition to plants and animals could induce the requirement 
that only plant and animal organisms are susceptible of being excluded. While this 
interpretation makes no sense scientifically, it might have some practical 
consequences. The term organism means a complex adaptive system of organs that 
influence each other in such a way that they function as a more or less stable whole 
and have properties of life. Plants and animals are organisms when taken as a whole. 
Should part of a plant or an animal be considered as plant or animal in the sense of the 
exclusion? Following the definition of an organism, it should be assumed that only 
part of a plant or an animal that is capable of propagation or development could be 
excluded. Hence, a gene originating from an animal or a plant cannot be considered as 
plants and animals, and should be capable of being patented. Whether a plant’s or 
animal’s cell including such gene must be patentable is then unclear. In addition, the 
question could be raised in the case of cell cultures. While they might have the 
capabilities to a certain extent of propagation and development, are they plants or 
animals within the meaning of Article 27.3(b)? What would be the situation with stem 
cells? Those cultures grow identical cells that tend to be independent from each other, 
hence might fall within the definition of a microorganism. While those distinctions 
are not important for agricultural activities, they could be much more sensitive in the 
research aspect of biotechnology as such. 
 
The exclusion of plants and animals seems to derive from the EPO approach. The 
Strasbourg Convention, 1963, which originated the Munich Convention (EPC), was 
concerned with the potential consequences of patent rights over certain breeding and 
farming activities, hence the exclusion of plant and animal variety as such under the 
EPC. The recent development in breeding activities is advocating the limited 
efficiency of the EPO approach. Indeed, it is of concern now that biotechnology 
allows circumventing the exclusion of plants and animals under the EPC, while their 
development is illustrating the current trend in breeding development. TRIPS 
provides a broader potential exclusion as it is not limited to varieties, hence it appears 
to be more integrative of new technologies toward the purpose of potentially 
excluding a patent regime that would affect breeding activities at large. While the 
distinction between microorganisms and plants or animals seems rather 
straightforward as to the purpose of the exclusion in the light of the final outcome, its 
implications becomes more problematic as to the technology behind breeding 
activities, as held above with biotechnology activity at the level of cells. 
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3. Microbiological processes 
 
Microbiological processes in a literal translation should stand for any processes that 
are being carried out by microorganisms. It does not make much sense scientifically 
to differentiate between macroorganism and microorganism in their biological activity 
as most of the complexity is held within the micro realm and is usually not 
categorized based on such considerations. To put it another way, the most 
fundamental biological processes are already achieved by microorganisms. Therefore, 
biological processes other than microbiological processes, in that context, should be 
understood as processes that could only occur in plants and animals, which should be 
highly dependant to matter relating to the size. Thus it identifies a subset of biological 
processes that are macro-biological processes. 
 
On the contrary, in the industry, the interpretation of the terms microbiological 
processes is focused on microorganisms in opposition to organisms at large. Thus, 
under such approach, microbiological processes are restricted to those that are specific 
to microorganisms and not to be found in other organisms. Hence, processes that are 
shared by all life forms, such as the synthesis of proteins, should then be included as 
biological processes. This approach adopts a different logic. In fact micro and macro 
biological processes are a subset of biological processes, thus one can oppose that the 
distinction between biological and microbiological processes ensures that only 
processes that exclusively occur in microorganisms shall be considered as patentable 
subject matter, the rest being left at the discretion of the Member State. 
 
The African Group in a communication to the WTO110 went even further. It opposed 
that microbiological processes should be potentially excludable as they were in 
essence biological processes. While this is scientifically true, again microbiological 
process are a subset of biological process, the way Article 27.3(b) is worded does not 
lead to such an interpretation. Hence, it is not held that biological processes at large 
should be potentially excluded, but those that are not microbiological, thus a 
distinction is created within the wording.  
 
Thus it appears that a very different approach might be taken depending on which 
aspect of the definition we are focusing on. If microbiological is opposed to 
biological, then only processes exclusive to microorganisms will be at stake. On the 
contrary if the definition assumes a large interpretation of the term microbiological 
process, then only biological processes that are not found in microorganisms are 
potentially excludable, thus processes that are exclusive to macro-organisms.  
 
It has to be noted that the purpose of the TRIPS Agreement is to promote the 
protection of intellectual property rights, patents in the present context. Consequently, 
such objective may enforce the fact that restriction may have to be interpreted in a 
narrow manner. This approach would favour the first interpretation that we made, 
which is that only processes that occur in macro-organisms may be excluded. In 
addition, such exclusion seems to derive from the EPC approach. The Strasbourg 
Convention, 1963, which originated the Munich Convention (EPC), was concerned 
with the potential consequences of patent rights over certain breeding and farming 
activities, thus focusing on processes that related to such practices.  
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4. Non-biological processes for the production of plants and animals 
 
Biological processes are defined as any processes that occur within and by the activity 
of living organisms. Non-biological processes are thus any processes that are not 
biological processes, being those that are not accomplished as such under natural 
conditions. In other terms, non-biological process will include any processes that 
require the action of man at a certain stage to create their occurrence. It may 
encompass propagation by cutting, hybridization, genetic engineering and so on. 
 
5. Essentially biological processes for the production of plants or animals  
 
What are potentially excludable from patent protection are essentially biological 
processes, the definition of which could be understood by the end of the provision, 
‘other than non-biological and microbiological processes’ that leads to the production 
of plants or animals.  
 
Therefore, it can first be appreciated that non-biological and microbiological 
processes shall be patentable subject matter, which includes those that lead to the 
production of plants and animals. Thus, whereas the wording under Article 27.3(b) 
may permit plants and animals to be excluded as patentable subject matter, certain 
processes for the production of plants and animals, especially those employed in 
biotechnology, shall be considered as patentable subject matter. Moreover, it is only 
when the purpose is for the production of plants and animals, that essentially 
biological processes can be excluded. Therefore an essentially biological process for 
the production of anything else than plants or animals is required to be capable of 
patent protection, as long as the requirement for patentability are met. 
 
Again, biological processes are defined as any processes that are occurring within and 
by the activity of living organisms. The opposition with non-biological processes and 
microbiological processes seems confusing scientifically, as explicated above, but the 
purpose of the TRIPS Agreement as well as some of the basis for such provision 
seems to restrict the nature of those processes to those that can only be witnessed in 
macro-organisms or strictly plants and animals.  
 
The use of the term ‘essentially’ holds no specific scientific meaning in that context 
and is only a matter of legal interpretation. It is used so as to include a legal 
qualitative criterion on how the exclusion should be operated. Thus, it introduces a 
qualitative degree on the interpretation of the exclusion. Instead of an absolute 
excludable subject matter, this should be understood under a substantive and 
qualitative approach. In other terms, if a set of processes, or a single multi-step 
process, which leads to the production of a plant includes a step that is biological, the 
exclusion should only be effective if the step is viewed as substantively essential. 
What makes a step substantially essential is undefined. 
 
The possible exclusion of essentially biological processes is restricted under ‘the 
production of plants and animals’ in general. Therefore, the processes are being 
potentially excludable where they are in relation to the genesis of plants or animals, 
those should include means of selection, breeding, reproduction, propagation, 
regeneration and so on. Hence, it is mainly processes of propagation at large and 
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selection from existing material that are excluded. It is the mechanistic processes that 
are at stake, while the acquired traits of the organism are not. While plants and 
animals might be excluded, a process that is not included in the definition provided 
above cannot. In practical terms, this means that a process to insert a gene of interest 
in a plant, for example, can be patented. But if the exclusion under patent protection 
for plants and animals is held, the product of such process, the new plant, cannot be 
enforced under a patent regime. IPR will then regulate the breeding activity rather 
than the agricultural practice, unless one utilizes a technological lock, such as the 
terminator gene.  
 
But it could be interpreted differently. Indeed, the point of view could be from the 
outcome in addition to the mechanistic approach to the development. The production 
of plants and animals would then embrace the organism at its final stage. Under that 
interpretation, every process that permitted such outcome will be potentially 
excludable. The focus there will be as to how the acquired traits are biological 
processes without being a microbiological process. In that case, the inclusion of a 
gene that originates from another macroorganism, being a feature not present in 
microorganism, could be excludable. An example could be the case of basmati rice. 
The identification of the gene that leads to the specific fragrance of basmati rice and 
its inclusion within another macroorganism could be excludable. Indeed, it is a macro-
biological process that leads to the production of another macroorganism by being 
inserted within the latter. On the contrary, the exclusion of a trait that originated in 
microorganism would not be permissible. A practical example would be the Bt 
technology that transmits in plants the capacity of generating a pesticide compound 
which originated in a microorganisms.  
 
The most general interpretation of the wording would read as: any processes, which 
are only occurring in macroorganisms, to the genesis of plants and animals in general 
(both macro and micro111), are potentially excludable from patent protection; the 
restriction being limited under a legal qualitative criterion. In other terms, what is 
being restricted are breeding methods, in a broader sense, that occur naturally in 
plants and animals.  
 
Under the EPC, ‘a process for the production of plants or animals is essentially 
biological if it consists entirely of natural phenomena such as crossing or selection’.112 
It has to be opposed with what is not ‘biological’ in that legal definition, which are 
microbiological and non-biological processes. Microbiological processes are ‘any 
process involving or performed upon or resulting in microbiological material’.113 
Non-biological processes are generally not specified as such, but seem to relate to 
those that are not occurring in nature. Hence, it appears that the EPC interpretation is 
specifically in line with the literal interpretation made previously.  
 
The key question arises in the interpretation of the term ‘essentially’. For a process to 
be essentially biological in the sense of the exclusion it requires that the substantial 
part of the claimed process is not within that exclusion. Hence, the fact that a process, 
which generally includes different steps, has one of its steps included in the restriction 
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must not in itself be a sufficient ground for exclusion. Meanwhile, the fact that one of 
the steps is either a microbiological process or a non-biological process will not make 
de facto the whole process capable of being patented. Under the EPC, one should take 
into account the totality of human intervention. For a process not to be an essentially 
biological process it will necessitate human intervention as to its capability of 
occurrence and the intervention should be viewed as non-trivial.114 In a famous 
landmark decision of the EPO,115 the Board analyzed each technical step to assess the 
level of human intervention as to the outcome. Hence, the term ‘essentially’ should 
address certain discretion as to the patentability of the process, which will balance the 
various aspects of the process under the assessment of what appears substantial as to 
the outcome. 
 
It appears that the distinction made under Article 27.3(b) is again to provide means to 
exclude, as patent subject matter, processes that are being used traditionally in 
breeding activities rather than non-traditional biotechnological processes as 
increasingly used in technologically advanced countries. All legal systems so far 
reviewed in this study seem to be concerned with basic breeding activities and appear 
to interpret those terms as restricting the potentially excludable subject matter to those 
that relate to means of reproduction or selection. Nevertheless, the distinction made 
previously under the scientific interpretation116 of the terms could hold under the 
TRIPS and address substantial effect as to the patentability of biotechnology breeding 
activities. 
 
7. Plant and animal varieties 
 
The scientific approach is not very conclusive in providing a straight definition as to 
what a plant variety is. In botany, the following distinctions have been identified: 
species, subspecies, varieties, subvarieties, forms, groups and cultivars. 
 
A species is constituted of members that are capable of interbreeding (the offspring is 
not sterile). A subspecies is the taxon immediately subordinate to species, which 
therefore has the same quality amongst its members as the one identified by a species 
plus another level of distinction. Its members differ morphologically and genetically 
from members of other subspecies. Varieties are normally mistaken with subspecies; 
they are used for lower degrees of distinction, if needed. A form is used to designate a 
minor variation within a population or region. For instance, white-flowered forms of 
species that usually have coloured flowers. Finally, a cultivar is a cultivated selection 
of a plant species that is vegetatively propagated, i.e. a clone, which means that its 
genetic pool is not affected by sexual reproduction. A good example would be a 
hybrid. 
 
So it appears from the basic scientific approach that a plant variety is something 
between a subspecies, which is a group having a certain extent of distinctive 
morphological and genetic characteristics that are being reproduced within the group, 
which is theoretically capable of interbreeding with other subspecies, and a form, 
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which holds all those features, but where the distinctive aspect is limited to one 
characteristic.  
 
While varieties can be differentiated based on the occurrence in nature and the various 
levels of distinction, the term has also evolved responding to the practice of the 
breeding activity. Hence, based on the mode of reproduction, the means of selection 
and the stability of the created variety, a necessity in that field, more functional 
definitions were made.117 Autogamous fixed varieties in pure lineage (wheat, green 
beans, soy, tomatoes…) are highly homogenous and easy to reproduce identically. 
Autogamous fixed varieties (eggplant, courgette, chilli…) are slightly less stable over 
reproduction cycles, but still acceptable. Allogamous homogenized fixed varieties 
(carrots, onions, cabbage…) originate from more heterogeneous populations and are 
generally selected for a specific trait. Hybrid varieties of first generation (wheat, 
colza, melon…) where the parents are fixed or pure lineage; hence have an inherent 
stability. Hybrid varieties of second generation are those where the first generation is 
not stable enough and requires another crossing to gain in stability. Clone varieties 
(tulip, iris, rosemary, apple and peer trees, wine, potatoes…) are reproduced 
asexually, therefore are extremely homogenous unless mutations occur. The list is 
non-exhaustive but is mentioned to illustrate the complexity of the term.  
 
So, depending on the purpose for differentiating living specimens, the term can be 
used differently and lead to various interpretations. While considering occurring 
varieties, naturalists will focus on an inherent cluster of biodiversity, distinguishing 
factions that present certain characteristics in common. Dissimilarly, a breeder will be 
concerned with the creation of new stable specimens. Whereas the acquired features 
of the new variety are obviously the purpose of such activity, the distinction is based 
on the stability of the creation rather than on a comparative analysis amongst the 
diverse variability and clusters that could be found in the species in question.  
 
Missing a clear cut definition of variety, two potential interpretations can be made for 
the requirement under Article 27.3(b) for a sui generis protection for plant varieties. 
On the one hand, because of the position of variety in the taxonomy, the general 
scientific definition, one could argue that TRIPS does not require the protection of 
anything that is above or below the variety, i.e. subspecies, form and cultivar for 
example. On the other hand, under the breeder’s definition, a variety is an entity that 
is below the taxon of species, presents certain different features and can be 
reproduced in a more or less stable manner. Hence, everything that corresponds to 
those criteria should be capable of being protected either under a patent regime or an 
effective sui generis system.  
 
The International Convention for the Protection of New Varieties of Plants, which is 
administered by the UPOV,118 defines the term variety as follows:119 
 
                                                
117
 Group on Study and Control Variety, www.geves.fr 
118
 Union pour la Protection des Obtentions Végétales 
119
 International Convention for the Protection of New Varieties of Plants of December 2, 1961, as 
revised in Geneva on November 10, 1972, on October 23, 1978, and on March 19, 1991, (commonly 
referenced as the UPOV 1991), Chapter I, Article 1(vi) 
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‘Plant variety’ means any plant grouping within a single botanical taxon of 
the lowest known rank, which grouping, irrespective of whether the conditions 
for the grant of a plant variety right are fully met, can be:  
- defined by the expression of the characteristics that results from a given 
genotype or combination of genotypes,  
- distinguished from any other plant grouping by the expression of at least 
one of the said characteristics, and 
- considered as a unit with regard to its suitability for being propagated 
unchanged. 
  
This definition is reproduced literally in the Council Regulation (EC) No 2100/94 of 
27 July 1994 on Community Plant Variety Rights, Chapter I article 5.2, as well as 
under the Implementing Regulations to the Convention on the Grant of European 
Patents, Chapter VI Rule 23b.  
 
An ‘effective’ sui generis protection for plant varieties was defined in the following 
terms by the USA communication to the WTO:120 
 
Any law establishing rights in property, whether of real, tangible or intangible 
property, including the various forms of intellectual property, must have 
certain characteristics if it is to be effective. Nature of the subject matter must 
be identified in the law clearly enough to enable those concerned to 
distinguish what falls within the scope of the law from what is beyond that 
scope. Must defines the characteristics or qualities that particular subject-
matter must possess to qualify for protection. Must also establish who is 
entitled to obtain property rights in particular subject matter, if particular 
procedures must be followed to obtain rights in particular subject matter and 
fees, if any limitations are to apply to these legal rights, and the period during 
which the rights are in force and the circumstances. Finally the legal actions 
available to the right holder to enforce its rights and the circumstances in 
which those actions may be taken must also be spelled out and so on….   
 
The UPOV standard seems to provide a sufficient system in that sense. It is not an 
ambit of this paper to address the way different Member States have implemented 
such requirement, thus we shall not consider this issue further. 
 
Animal varieties are generally defined in science as a subgroup of species. Therefore 
they are theoretically capable of reproduction with other subgroup, but are 
differentiated with a set of characteristics that appears somehow reproduced within 
the same subgroup. A good example would be a dog pedigree. The distinction 
between animal and animal varieties is not required under TRIPS but is being 
provided as it is a matter of exclusion for patentability in certain Member States such 
as the States signatory to the European Patent Convention. 
 
7. Genes 
 
Genes are obviously of central importance to the development and value of 
biotechnology. The core aspect of biotechnology is to engineer new organisms that 
                                                
120
 IP/C/W/209 WTO 
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incorporate certain traits of interest, traits that are the function of gene expression or 
non expression. Article 27.3(b) of TRIPS does not mention as such the term gene in 
the possible exclusions. Thus under a first appreciation, genes must be capable of 
being patented, reflecting the implications of Article 27.1 of TRIPS. Following the 
development made above, it seems that under certain interpretations, the term gene 
might be implied or capable of being incorporated in some of the exclusions.  
 
They can be simply defined as ‘unit of heredity which is transferred from a parent to 
offspring and is held to determine some characteristic of the offspring; in particular, a 
distinct sequence of DNA forming part of a chromosome’.121 Thus, by definition, they 
are parts of any organisms and are involved in determining the characteristics of an 
organisms, thus their expression have a biological role.  
 
Under Article 27.3(b), plants and animals may be excluded from being patentable 
subject matter. The question may be raised as to the implications of the terms plants 
and animals. Are they to be conceived as whole organisms, or can the exclusion apply 
to parts of them? Under the later approach, genes could then potentially be excluded 
under Article 27.3(b) TRIPS. On the issue whether a plant or an animal has to be 
considered as a whole to be excluded, it seems that more restrictive legislations will 
be specific in the wording of their exclusion rather than including those concerns 
within a definition.122 Genes, under the EPO, JPO, USPTO are not considered as life 
forms but rather as chemical compounds, however even if they were, those patent 
regime are not excluding life forms as such. It is also interesting to note that under 
Article 5.3 of the same Council Regulation (EC) No 2100/94 is held that 
 
A plant grouping consists of entire plants or parts of plants as far as such parts 
are capable of producing entire plants, both referred to hereinafter as ‘variety 
constituents’ 
 
Thus, it seems that under such regulation, the distinction as such between whole or 
parts is irrelevant; what matters is whether the subject matter is capable of producing 
an entire plant. This would be in line with the original reasoning behind such 
exception, which is to free certain breeding activity from patent protection. In the 
meantime, it is to be noted that breeding activity has evolved and is now deeply 
involved with technology based on the use of specific genes, thus it might still be 
implied in the purpose of the exclusion while adapting to modern technology.  
 
In addition, also considered above, genes are the informational bases that define the 
characteristics of an organism. The information encoded is generally translated to 
proteins, which have a biological role. Thus a gene as such is what governs most 
biological processes. So, whereas a gene as such, being a product, may not be 
excluded as an essentially biological process, the use made of the gene could; 
especially when such traits is being selected from another plant or animal.   
 
Review of the terms 
 
                                                
121
 Concise Oxford English Dictionary 
122
 Andean Community Decision 486, Brazilian Patent Act, Indian Patent Act.  
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Plant: Organisms that grow out of inorganic material by photosynthesis. They lack 
ability to move around their environment except by growing or being transported by 
wind, water, or external forces. They comprise: mosses, ferns, woody and non-woody 
flowering plants. 
 
Animal: Organisms that ingest food instead of absorbing or photosynthesizing it. 
They also have their own means of locomotion in at least one phase of their life cycle. 
They comprise: Sponges, worms, insects, fish, amphibians, reptiles, birds and 
mammals. 
 
Organism: a complex adaptive system of organs that influence each other in such a 
way that they function as a more or less stable whole and have properties of life. 
 
Microorganism: Any organism that cannot be seen by the naked eye, generally in the 
range of 10-5 m.   
 
Variety: Any of various groups of plants or animals within a species that is 
distinguished from other groups by characteristics not constant enough or too trivial to 
distinguish species.123 
 
Essentially: To be defined legally 
 
Biological process: Any process that results from the activity of a life form. 
 
Micro-biological process: Any process that results from the activity of a life form 
when said life form is a micro-organism. 
 
Non-biological processes: Any process that requires the intervention of man. 
 
                                                
123
 Britannica Webster. Encyclopaedia Britannica 
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8. TOWARDS OPTIMAL PRO-BIOTECH PATENT REGIMES 
 
So can we rank developing countries according to their biotechnological 
capacities? 
 
Are we capable of measuring and thereby ranking the biotechnological capacities of 
different developing countries so as to determine the most efficient way countries 
should take advantage of the flexibilities of Article 27.3(b) of TRIPS? Earlier 
discussion particularly in Chapter 3 would suggest that this is a difficult thing to do 
since no 100% reliable schemas or indices have yet been devised, certainly not the 
ones we reviewed earlier which comprise all of the well-known ones. Needless to say 
perhaps, such a task is possible but requires further research. 
 
The three developing countries that we looked at are widely acknowledged to be 
among the more advanced developing countries in terms of biotech capacity and 
potential, especially India. Indeed, India’s biotech sector stands apart from almost 
every other developing country in its size and potential. Yet even here, the ability of 
India’s commercial biotechnology sector to take advantage of the patent system is still 
quite limited at this time.  
 
As for attracting FDI, India is becoming more successful with life science 
corporations setting up research and development facilities in the country. Since 
India’s patent system is still considered by many transnational corporations to be 
inadequate, the existence of a large number of well-qualified and inexpensive-to-hire 
Indians able to do the research and the enormous growth potential of such a high-
population market are likely to be far more significant factors than the patent regime 
how ever it may be designed. That is not to say that a more expansive patent regime 
would not necessarily spur accelerated biotech research-oriented FDI. We have no 
evidence to counter such a scenario, and therefore cannot rule it out. Nonetheless the 
growth of such investment has so far not been directly influenced by changes to the 
patent regime and has more to do with the relative cheapness of doing high quality 
research in India compared to Europe and North America. 
 
The implementation menu 
 
Regulating biotechnology, a new, complex, expensive, research-intensive and rapidly 
advancing field presents particular challenges for developing country policymakers. If 
they lack a clear idea of how – and even whether – biotechnology can benefit their 
economies and improve the lives of their citizens, they are in no position to design a 
patent system to promote welfare-enhancing biotechnological innovation. Moreover, 
many of these countries have no biotechnology industries to speak of, and there is 
every reason to be highly sceptical that such businesses will spring up just because 
life-forms and micro- and non-biological processes can be patented. And yet, they 
have obligations under international IP law to provide patent protection for at least 
some types of biotechnological invention. What is a developing country government 
to do?  
 
On the basis of what we have covered so far, we present three different ways to 
implement Article 27.3(b). Option 1 (Table 1) we call the ‘no exceptions option’. This 
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more or less reflects US practice and is unlikely to be optimal for any developing 
country.  
 
Table 1: Biotech patenting in TRIPS: the ‘no exceptions option’ 
 
PROVIDE 
Microorganisms (broadly defined) 
 
Animals and plants (including plant varieties by patents 
and an effective sui generis system) and their parts 
including seeds, somatic cells, gametes, cells, genes 
 
Non-biological processes 
Essentially micro- and macro biological processes  
 
Plant varieties also (either by patents or by or by any 
combination thereof) 
 
 
Option 2 (Table 2) is the ‘all exceptions option’ which incorporates all of the 
exceptions while construing the terminology widely or narrowly so that what must be 
provided is the absolute minimum that is legally acceptable and scientifically 
reasonable, while as much subject matter as possible is kept outside the patent system.  
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Table 2: Biotech patenting in TRIPS: the ‘all exceptions option’ 
  
PROVIDE EXCLUDE 
Microorganisms (narrowly 
defined, e.g. unicellular 
organisms in the range of 
10-5 m maximum size.) 
Whole animals and plants 
(including plant varieties) and 
their parts including seeds, 
somatic cells, gametes, genes 
and gene products 
 
 
Microbiological processes 
that are specific to 
microorganisms 
 
Essentially biological processes 
for the production of plants or 
animals (even with substantial 
human intervention) 
Non-biological processes 
 
 
Plant varieties (only by an 
effective sui generis system, 
e.g. modelled on UPOV 
1988) 
 
 
 
Option 3 (Table 3) is the ‘some exceptions option’. It is not really a single option and 
the table below aims merely to provide some examples of exclusions and 
interpretations. Between Options 1 and Options 2 lie a whole range of possibilities 
between the two extremes, and the table provides just a few of these. 
Table 3: Biotech patenting in TRIPS: the ‘some exceptions option’ 
  
PROVIDE EXCLUDE 
Microorganisms (narrowly 
defined) 
 
Whole animals and plants 
Microbiological processes 
found in microorganisms 
that are found in larger 
organisms too. 
 
Essentially biological processes 
for the production of plants or 
animals 
Non-biological processes  
 
 
Plant varieties (only by an 
effective sui generis system, 
e.g. modelled on UPOV 
1988 or 1991) 
 
 
Genes (as chemicals with 
specified function) 
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In this study we have been sceptical about the methods available for assessing the 
biotechnological capacities of developing countries, and explained why calling for 
more research in this area and, one hopes, making the case this is vitally important. 
However our survey of three relatively advanced developing countries highlighted 
that in this recent and rapidly advancing field of technology most if not all of the 
developing world lags far behind countries like the United States, Japan and such 
European countries as the UK, Germany and France. Therefore, and taking into 
account the work of researchers like Lall and Kim, for the overwhelming majority of 
developing countries the all exceptions option is for the time being the most rational 
basis for biotech related patent rulemaking. However for the most advanced of the 
developing countries which are beginning to innovate and seek to develop their 
inventions either alone or in collaboration with foreign corporations, some elements 
of option 2 may now be desirable.    
 
From policytaking to policymaking 
 
Historical evidence shows that well designed IPR systems can benefit national 
economies just as poorly designed ones can harm them. But how does one go about 
designing and negotiating an appropriate IPR system or fine-tuning an existing one? 
The economic and social impact of IPR reform is very hard to predict reliably, 
especially in the long-term. This is particularly the case for developing countries. This 
is a real handicap in the present situation where countries are pressured to negotiate 
and implement new multilateral trade rules, bilateral or regional free trade or 
investment agreements, and to respond to powerful stakeholder groups – often foreign 
ones – demanding changes to national regimes that may not serve the interests of their 
citizens and other domestic stakeholders. Such difficulties in measuring impacts make 
it difficult for governments and their representatives to know what negotiating 
position to adopt on IP, how best to handle complex trade issue-linkage bargains, and 
how far they should accommodate the demands of international business interests 
clamouring for change to domestic IP rules. 
 
As with other areas of business regulation, IP policymaking and negotiation position 
formation is, or at least should be, a matter for national decision making involving the 
collaboration of all national stakeholders including owners, users and the public. 
Foreign interests should not be ignored but government business regulation is about 
what is good for the national economy and the country’s citizens. Good policymaking 
cannot be based solely on the implementation of obligations accepted in multilateral 
treaties or regional or bilateral trade agreements. Unfortunately, policymaking often 
seems to be done in this way, which is to say that policytaking is the norm rather than 
policymaking. What we have here are political and technical challenges. So as to 
better overcome the challenges, and as Workpackage 4 of the IPDEV project on 
technical assistance provision concludes, technical assistance providers themselves 
have much to learn. In the present context, they and others claiming to be authorities 
on how to design biotech patent regimes sensitive to the specificities of individual 
countries must provide convincing objective evidence for their prescriptions. And 
recipient countries must of course demand such evidence. 
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ANNEX 1 
PROTECTION OF ANIMALS UNDER A PATENT REGIME 
 
Countries 
or Regional 
Agreements 
Patentability of the Subject Matter Other relevant provisions 
EPC 
Member 
States  
EPC 
- Art. 53 (b) EPC Exclusion of… plant or animal 
varieties […] 
- Rule 23c(b) plants or animals if the technical 
feasibility of the invention is not confined to a 
particular plant or animal variety; EPC 
 
 
EPC 
- Rule 23d(d) 
processes for modifying the genetic identity of animals which are likely to cause 
them suffering without any substantial medical benefit to man or animal, and also 
animals resulting from such processes. 
 
European 
Union 
Directive 98/44/EC 
- Art 4.  
1. The following shall not be patentable: 
(a) plant and animal varieties; 
2. Inventions which concern plants or animals shall be 
patentable if the technical feasibility of the invention is 
not confined to a particular plant or animal variety. 
 
Directive 98/44/EC 
- Preamble (27) Whereas if an invention is based on biological material of plant or 
animal origin or if it uses such material, the patent application should, where 
appropriate, include information on the geographical origin of such material, if 
known; whereas this is without prejudice to the processing of patent applications or 
the validity of rights arising from granted patents; 
- Preamble (45) Whereas processes for modifying the genetic identity of animals 
which are likely to cause them suffering without any substantial medical benefit in 
terms of research, prevention, diagnosis or therapy to man or animal, and also 
animals resulting from such processes, must be excluded from patentability; 
- Art 8 
1. The protection conferred by a patent on a biological material possessing specific 
characteristics as a result of the invention shall extend to any biological material 
derived from that biological material through propagation or multiplication in an 
identical or divergent form and possessing those same characteristics. 
 
Japan Patentable, no restrictions  
ARIPO Patentable, no restrictions  
OAPI BA – Section 1  
- Art 6(c) inventions having as their subject matter 
plant varieties, animal species and essentially 
biological processes for the breeding of plants or 
animals other than microbiological processes and the 
products of such processes; 
No specific exclusions under Utility Model protection 
Andean 
Community 
ACD 
- Art 15.  
The following shall not be considered inventions: 
b) Any living thing, either complete or partial, as found 
in nature, natural biological processes, and biological 
material, as existing in nature, or able to be separated, 
including the genome or germplasm of any living 
thing; 
- Art 20  
The following shall not be patentable:  
c) plants, animals, and essentially biological processes 
for the production of plants or animals other than non-
biological or microbiological processes;   
ACD 
- Art 3 
The Member Countries shall ensure that the protection granted to intellectual 
property elements shall be accorded while safeguarding and respecting their 
biological and genetic heritage, together with the traditional knowledge of their 
indigenous, African American, or local communities. As a result, the granting of 
patents on inventions that have been developed on the basis of material obtained 
from that heritage or that knowledge shall be subordinated to the acquisition of that 
material in accordance with international, Andean Community, and national law. 
- Art 53  
A patent owner may not exercise the right referred to in the previous article with 
respect to the following acts:  
e) where the patent protects biological material that is capable of being reproduced, 
except for plants, using that material as a basis for obtaining a viable new material, 
except where the patented material must be used repeatedly to obtain the new 
material.  
- Art 54  
Where the patent protects biological material that is capable of being reproduced, 
the patent coverage shall not extend to the biological material that is obtained by 
means of the reproduction, multiplication, or propagation of the material that was 
introduced into the commerce as described in the first paragraph, provided that it 
was necessary to reproduce, multiply, or propagate the material in order to fulfill 
the purposes for which it was introduced into commerce and that the material so 
obtained is not used for multiplication or propagation purposes. 
- Art 82 
Processes and materials excluded from patent protection may not be the subject 
matter of utility model patents.  
United 
States of 
America 
USC 
Sec 100 
Whoever invents or discovers any new and useful 
process, machine, manufacture, or composition of 
matter, or any new and useful improvement thereof, 
may obtain a patent therefor, subject to the conditions 
and requirements of this title. 
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Canada No specific restrictions  
Australia APA-  
-Patentable, no restrictions for standard patents 
 
 
APA 
- Innovation patents: 
Part 3 Art 18 (1A) 
(3) For the purposes of an innovation patent, plants and animals, […] are not 
patentable invention 
(4) Subsection (3) does not apply if the invention is a microbiological process or a 
product of such process 
Singapore Patentable, no restrictions   
Brazil BPA  
Art 10 The following are not considered to be 
invention 
(IX) – natural living beings, in whole or in part. 
 
Art. 18 The following are not patentable:  
(III) living beings, in whole or in part, except 
transgenic micro-organisms meeting the three 
patentability requirements […] 
 
Russian 
Federation 
PLRF  
Art 4(3) 
The Following shall not be deemed patentable: plant 
varieties and animal breeds 
PLFR  
Art 5(1)  
A technical solution relating to a device shall be protected as utility model. (no 
further restrictions) 
India IPA 
Chp II  
3 (h) a method of agriculture or horticulture  
(i)any process for the medicinal, surgical, curative, 
prophylactic or other treatment of human beings or any 
process for a similar treatment of animals or plants to 
render them free of disease or to increase their 
economic value or that of their products.  
(j) .  plants and animals in whole or any part thereof 
other than microorganisms but including seeds, 
varieties and species and essentially biological 
processes for production or propagation of plants and 
animals. 
 
China PLC  
Art 25(4)  
No patent shall be granted: (4) animals and plant 
varieties. 
 
Thailand PAT 
Art 9  
The following inventions are not protected under this 
Act (1) naturally occurring organisms and their 
components, animals, plants or extracts from animals 
or plants 
 
Malaysia MPA  
Sec 13 (1) the following shall not be patentable 
(a) Plant or animal varieties or essentially biological 
processes for the production of plants or animals, other 
than man-made living micro-organisms, micro-
biological processes and the products of such micro-
organism processes; 
 
Indonesia Patentable, no restrictions  
Philippines IPCP  
Sec.22 –  
Non Patentable inventions: (4) Plant varieties or animal 
breeds or essentially biological process for the 
production of plants or animals. This provision shall 
not apply to micro-organisms and non-biological and 
microbiological processes.  
 
Tunisia TPL 
Art. 3 
Les variétés végétales, les races animales ou les 
procédés essentiellement biologiques d’obtention de 
végétaux ou d’animaux. Toutefois, cette disposition ne 
s’applique pas aux procédés biologiques médicaux et 
aux produits obtenus par ces procédés; 
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ANNEX 2 
PROTECTION OF PLANTS UNDER A PATENT REGIME 
 
 
Countries 
or Regional 
Agreements 
Extent of patentability Other relevant provisions Definitions 
EPC 
Member 
States 
EPC 
-Art. 53 (b)  
Exclusion of… plant or animal varieties 
[…] this provision does not apply to 
microbiological processes or the 
products thereof.  
-Rule 23c(b) plants or animals if the 
technical feasibility of the invention is 
not confined to a particular plant or 
animal variety; 
 
 EPC 
Rule 23b (4)  
‘Plant variety’ means any plant grouping 
within a single botanical taxon of the lowest 
known rank, which grouping, irrespective of 
whether the conditions for the 
grant of a plant variety right are fully met, can 
be: 
(a) defined by the expression of the 
characteristics that results from a given 
genotype or combination of genotypes, 
(b) distinguished from any other plant 
grouping by the expression of at least one of 
the said characteristics, and 
(c) considered as a unit with regard to its 
suitability for being propagated unchanged. 
  
European 
Union 
Directive 44/98/EC 
Art 4 
1. The following shall not be patentable: 
(a) plant and animal varieties; 
2. Inventions which concern plants or 
animals shall be patentable if the 
technical feasibility of the invention is 
not confined to a particular plant or 
animal variety. 
 
 
 
 
 
 
 
 
 
 
 
Directive 44/98/EC 
Art 2(2)  
A process for the production of plants or 
animals is essentially biological if it consists 
entirely of natural phenomena such as crossing 
or selection. 
Art 8 
1. The protection conferred by a patent on a 
biological material possessing specific 
characteristics as a result of the invention shall 
extend to any biological material derived from 
that biological material through propagation or 
multiplication in an identical or divergent form 
and possessing those same characteristics. 
Preamble(27) Whereas if an invention is based 
on biological material of plant or animal origin 
or if it uses such material, the patent 
application should, where appropriate, include 
information on the geographical origin of such 
material, if known; whereas this is without 
prejudice to the processing of patent 
applications or the validity of rights arising 
from granted patents; 
Art 11 
1. By way of derogation from Articles 8 and 9, 
the sale or other form of commercialisation of 
plant propagating material to a farmer by the 
holder of the patent or with his consent for 
agricultural use implies authorisation for the 
farmer to use the product of his harvest for 
propagation or multiplication by him on his 
own farm, the extent and conditions of this 
derogation corresponding to those under 
Article 14 of Regulation (EC) No 2100/94. 
 
Preamble(29) Whereas this Directive is 
without prejudice to the exclusion of plant and 
animal varieties from patentability; whereas on 
the other hand inventions which concern plants 
or animals are patentable provided that the 
application of the invention is not technically 
confined to a single plant or animal variety; 
 
Directive 44/98/EC 
 (30) Whereas the concept ‘plant variety’ is 
defined by the legislation protecting new 
varieties, pursuant to which a variety is 
defined by its whole genome and therefore 
possesses individuality and is clearly 
distinguishable from other varieties; 
(31) Whereas a plant grouping which is 
characterized by a particular gene (and not its 
whole genome) is not covered by the 
protection of new varieties and is therefore not 
excluded from patentability even if it 
comprises new varieties of plants; 
(32) Whereas, however, if an invention 
consists only in genetically modifying a 
particular plant variety, and if a new plant 
variety is bred, it will still be excluded from 
patentability even if the genetic modification is 
the result not of an essentially biological 
process but of a biotechnological process; 
 
 
Japan Patentable, no restrictions   
ARIPO Patentable, no restrictions   
OAPI BA  
Section 1  
No specific exclusion under Utility Models  
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Art. 6(c) inventions having as their 
subject matter plant varieties, animal 
species and essentially biological 
processes for the breeding of plants or 
animals other than microbiological 
processes and the products of such 
processes; 
Andean 
Community 
ACD 
Art 15  
The following shall not be considered 
inventions: 
b) Any living thing, either complete or 
partial, as found in nature, natural 
biological processes, and biological 
material, as existing in nature, or able to 
be separated, including the genome or 
germ plasm of any living thing;  
Art. 20  
The following shall not be patentable:  
c) plants, animals, and essentially 
biological processes for the production of 
plants or animals other than non-
biological or microbiological processes;  
 
ACD 
Art 3 
The Member Countries shall ensure that the 
protection granted to intellectual property 
elements shall be accorded while safeguarding 
and respecting their biological and genetic 
heritage, together with the traditional 
knowledge of their indigenous, African 
American, or local communities. As a result, 
the granting of patents on inventions that have 
been developed on the basis of material 
obtained from that heritage or that knowledge 
shall be subordinated to the acquisition of that 
material in accordance with international, 
Andean Community, and national law. 
Art 54  
Where the patent protects biological material 
that is capable of being reproduced, the patent 
coverage shall not extend to the biological 
material that is obtained by means of the 
reproduction, multiplication, or propagation of 
the material that was introduced into the 
commerce as described in the first paragraph, 
provided that it was necessary to reproduce, 
multiply, or propagate the material in order to 
fulfill the purposes for which it was introduced 
into commerce and that the material so 
obtained is not used for multiplication or 
propagation purposes. 
Art. 82 
Processes and materials excluded from patent 
protection may not be the subject matter of 
utility model patents. 
 
United 
States of 
America 
No specific restrictions  Plant Patent 
 
only relevant to the means of reproduction 
 
 
Canada No specific restrictions   
Australia APA-  
-Patentable, no restrictions for standard 
patents 
- Innovation patents: 
Part 3 Art. 18 (1A) 
(3) For the purposes of an innovation 
patent, plants and animals, […] are not 
patentable invention 
(4) Subsection (3) does not apply if the 
invention is a microbiological process or 
a product of such process 
  
Singapore Patentable, no restrictions    
Brazil BPA  
Art. 10 The following are not considered 
to be invention 
(IX) – natural living beings, in whole or 
in part. 
BPA 
Art. 18 The following are not patentable:  
(III) living beings, in whole or in part, except 
transgenic micro-organisms meeting the three 
patentability requirements […] 
 
Costa Rica    
Russian 
Federation 
PLRF  
Art 4(3) 
The Following shall not be deemed 
patentable: plant varieties and animal 
breeds 
PLFR  
Art. 5 (1) A technical solution relating to a 
device shall be protected as utility model. (no 
further restrictions) 
 
India IPA 
Chp II  
3 (h) a method of agriculture or 
horticulture  
(i)any process for the medicinal, surgical, 
curative, prophylactic or other treatment 
of human beings or any process for a 
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similar treatment of animals or plants to 
render them free of disease or to increase 
their economic value or that of their 
products.  
(j) .  plants and animals in whole or any 
part thereof other than microorganisms 
but including seeds, varieties and species 
and essentially biological processes for 
production or propagation of plants and 
animals. 
China PLC 
Art. 25(4) No patent shall be granted: (4) 
animals and plant varieties. 
  
Thailand PAT- 
Art. 9 The following inventions are not 
protected under this Act (1) naturally 
occurring organisms and their 
components, animals, plants or extracts 
from animals or plants 
  
Malaysia MPA – Sec. 13 (1) the following shall 
not be patentable 
(a) Plant or animal varieties or 
essentially biological processes for the 
production of plants or animals, other 
than man-made living micro-organisms, 
micro-biological processes and the 
products of such micro-organism 
processes; 
  
Indonesia Patentable, no restrictions   
Philippines IPCP – Sec.22 - Non Patentable 
inventions: (4) Plant varieties or animal 
breeds or essentially biological process 
for the production of plants or animals. 
This provision shall not apply to micro-
organisms and non-biological and 
microbiological processes. 
  
Tunisia TPL 
Art. 3 
Les variétés végétales, les races animales 
ou les procédés essentiellement 
biologiques d’obtention de végétaux ou 
d’animaux. Toutefois, cette disposition 
ne s’applique pas aux procédés 
biologiques médicaux et aux produits 
obtenus par ces procédés; 
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ANNEX 3 
ESSENTIALLY BIOLOGICAL PROCESSES FOR  
THE PRODUCTION OF PLANTS AND ANIMAL 
 
 
Countries 
or Regional 
Agreements 
Extent of Patentability Other relevant provisions Product originating 
directly from process 
Definitions 
EPC 
Member 
States 
EPC 
Rule 23b(5) A process for the 
production of plants or animals 
is essentially biological if it 
consists entirely of natural 
phenomena such as crossing or 
selection. 
 
EPC 
Rule 23d(d) processes for modifying 
the genetic identity of animals which 
are likely to cause them suffering 
without any substantial medical 
benefit to man or animal, and also 
animals resulting from such processes. 
 
 EPC 
Rule 23b 
(5) A process for the 
production of plants or 
animals is essentially 
biological if it consists 
entirely of natural 
phenomena such as 
crossing or selection. 
(6) ‘Microbiological 
process’ means any 
process involving or 
performed upon or 
resulting in 
microbiological material. 
 
European 
Union 
Directive 44/98/EC 
Art 4.  
1. The following shall not be 
patentable: 
 (b) essentially biological 
processes for the production of 
plants or animals. 
 
Directive 44/98/EC 
Preamble(29) Whereas this Directive 
is without prejudice to the 
exclusion of plant and animal varieties 
from 
patentability; whereas on the other 
hand inventions 
which concern plants or animals are 
patentable 
provided that the application of the 
invention is 
not technically confined to a single 
plant or animal 
variety; 
 
Directive 44/98/EC 
Art. 8(2). The protection 
conferred by a patent on a 
process 
that enables a biological material 
to be produced 
possessing specific 
characteristics as a result of the 
invention shall extend to 
biological material directly 
obtained through that process 
and to any other biological 
material derived from the 
directly obtained biological 
material through propagation or 
multiplication in an 
identical or divergent form and 
possessing those same 
characteristics. 
 
Directive 44/98/EC 
Art. 2.  
A process for the 
production of plants or 
animals is 
essentially biological if it 
consists entirely of natural 
phenomena such as 
crossing or selection. 
 
 
Japan Patentable, no restrictions    
ARIPO Patentable, no restrictions    
OAPI BA  
Section 1  
Art. 6(c) inventions having as 
their subject matter plant 
varieties, animal species and 
essentially biological processes 
for the breeding of plants or 
animals other than 
microbiological processes and 
the products of such processes; 
BA  
Section 2 
Utility models are not excluding 
anything specifically 
 
 
BA 
Section 1 
Art. 7(3)(b)(ii) engaging in the 
acts mentioned in subparagraph 
(a) above in relation to a 
product resulting directly from 
the use of the process. 
 
 
Andean 
Community 
ACD 
Art. 15.- The following shall not 
be considered inventions: 
b) Any living thing, either 
complete or partial, as found in 
nature, natural biological 
processes, and biological 
material, as existing in nature, or 
able to be separated, including 
the genome or germ plasm of 
any living thing; 
 
Art. 20  
The following shall not be 
patentable:  
ACD 
Art 54  
Where the patent protects biological 
material that is capable of being 
reproduced, the patent coverage shall 
not extend to the biological material 
that is obtained by means of the 
reproduction, multiplication, or 
propagation of the material that was 
introduced into the commerce as 
described in the first paragraph, 
provided that it was necessary to 
reproduce, multiply, or propagate the 
material in order to fulfill the purposes 
for which it was introduced into 
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c) plants, animals, and 
essentially biological processes 
for the production of plants or 
animals other than non-
biological or microbiological 
processes;  
commerce and that the material so 
obtained is not used for multiplication 
or propagation purposes. 
 
Art. 82 
Processes and materials excluded 
from patent protection may not be the 
subject matter of utility model patents. 
United 
States of 
America 
No specific restrictions   USC  
103 (b) 
(3) For purposes of 
paragraph (1), the term 
‘biotechnological process’ 
means-(A) a process of 
genetically altering or 
otherwise inducing a 
single- or multi-celled 
organism to-(i) express an 
exogenous nucleotide 
sequence, (ii) inhibit, 
eliminate, augment, or alter 
expression of an 
endogenous nucleotide 
sequence, or (iii) express a 
specific physiological 
characteristic not naturally 
associated with said 
organism; 
(B) cell fusion procedures 
yielding a cell line that 
expresses a specific 
protein, such as a 
monoclonal antibody; and 
(C) a method of using a 
product produced by a 
process defined by 
subparagraph (A) or (B), or 
a combination of 
subparagraphs (A) and (B). 
 
Canada CPA 
Sect. 2 
‘invention’ means any new and 
useful art, process, machine, 
manufacture or composition of 
matter, or any new and useful 
improvement in any art, process, 
machine, manufacture or 
composition of matter; 
(No specific restrictions) 
   
Australia APA  
-Patentable, no restrictions for 
standard patents 
 
- Innovation patents: 
Part 3 Art. 18 (1A) 
(3) […] the biological processes 
for the generation of plants and 
animals are not patentable 
invention 
(4) Subsection (3) does not 
apply if the invention is a 
microbiological process or a 
product of such process  
   
Singapore Patentable, no restrictions     
Brazil BPA   
Art. 10 The following are not 
considered to be invention 
(IX) natural biological 
processes.   
 BPA  
Art 43  
A patent confers on its 
proprietor the right to prevent 
third parties from […] 
(II) – a process, or product 
directly obtained by a patented 
process 
 
Russian 
Federation 
 No specific restrictions PLFR  
Art. 5 (1) A technical solution relating 
PLFR 
Art. 10 
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to a device shall be protected as utility 
model. (no further restrictions) (no 
processes) 
[…] performance of acts, stated 
in subparagraph two hereunder, 
in respect to a product obtained 
directly derived by a patented 
process.  
India IPA 
Chp II  
3 (h) a method of agriculture or 
horticulture  
(i)any process for the medicinal, 
surgical, curative, prophylactic 
or other treatment of human 
beings or any process for a 
similar treatment of animals or 
plants to render them free of 
disease or to increase their 
economic value or that of their 
products.  
(j) plants and animals in whole 
or any part thereof other than 
microorganisms but including 
seeds, varieties and species and 
essentially biological processes 
for production or propagation of 
plants and animals. 
   
China PLC 
Art.25 
For processes used in producing 
products referred to items (4) of 
the preceding paragraph patent 
right may be granted in 
accordance with the provisions 
of this Law.  
   
Thailand PTA 
Art. 36(2) where the subject 
matter of a patent is a process… 
have in possession ofr sale offer 
for sale or import the product 
produced by the patented 
process 
   
Malaysia MPA  
Sec. 13 (1) the following shall 
not be patentable 
(a) Plant or animal varieties or 
essentially biological processes 
for the production of plants or 
animals, other than man-made 
living micro-organisms, micro-
biological processes and the 
products of such micro-organism 
processes; 
 MPA  
Sec. 36(3)(b)(ii) 
Doing any of the acts referred 
[…] in respect of a product 
obtained directly by means of 
the process. 
 
Indonesia Patentable, no restrictions    
Philippines IPCP  
Sec.22 - Non Patentable 
inventions: (4) Plant varieties or 
animal breeds or essentially 
biological process for the 
production of plants or animals. 
This provision shall not apply to 
micro-organisms and non-
biological and microbiological 
processes. 
 IPCP  
Sec.71(1)(b) 
Where the subject matter of a 
patent is a process, to restrain, 
prevent or prohibit any 
unauthorized person or entity 
from using the process, and from 
manufacturing, dealing in, using, 
selling or offering for sale or 
importing any products obtained 
directly or indirectly from such 
process. 
 
Tunisia TPL 
Art. 3 
Les variétés végétales, les races 
animales ou les procédés 
essentiellement biologiques 
d’obtention de végétaux ou 
d’animaux. Toutefois, cette 
disposition ne s’applique pas 
aux procédés biologiques 
médicaux et aux produits 
obtenus par ces procédés;cédés; 
 TPL 
Art. 46 (c) 
Protection on the product 
directly obtained by means of 
the process. 
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ANNEX 4 
LIST OF LAWS 
 
 
Andean Community – ACD - Decision 486: Common Regime on Industrial Property 
 
Australia – APA - Patents Act 1990 (including amendments up to Act No. 120 of 
2004) 
 
ARIPO - Protocol on Patents and Industrial Designs within the framework of the 
African Regional Industrial Property Organization (including amendments 2001) 
 
Brazil – BPL - Law No 9,279 of May 14, 1996 
  
Canada – Canadian Patent Act – R.S. 1985, c. P-4 
 
China – PLC - Patent Law of the People’s Republic of China (including amendments 
of 2000) 
 
EPC Member States- EPC – European Patent Convention (text of the Convention and 
implementing regulations) 
 
European Union – Council Regulation No 2100/94 on Community Plant Variety 
Rights - CPVR 
  
European Union – Directive 98/44/EC on the legal protection of biotechnological 
inventions 
 
India – IPA - Indian Patent Act (including amendments of 2005) 
 
Indonesia – PLI - Law 6/1989 on Patents 
 
Japan – JPL - Japan Patent Law  
 
Malaysia – MPA - Patent Act 1983 (Incorporating amendment Act A1137/2002) 
 
OAPI- BA - African Intellectual Property Organization – Agreement Revising the 
Bangui Agreement of March 1997 
 
Philippines – IPCP - Intellectual Property Code of the Philippines – Republic Act 
No.8293 
 
Russian Federation – PLFR - Patent Law of the Russian Federation 1992, 3517 
(including amendments 22-FZ) 
 
Singapore – SPA –Statutes of the Republic of Singapore - Patent Act 21 of 1994 
(including amendments of 2004) 
 
South Korea – SKPA - Patent Act (Act No. 950, last amended by Act No. 6768, 2002) 
 78 
 
Thailand – PAT - Patent Act B.E. 2542 (As Amended by the Patent Act (No. 2) B.E 
2535 (1992) and the Patent Act (No. 3) B.E. 2542 (1999)) 
 
Tunisia – TPL - Law No 2000-84 on Patents 
 
United States of America – USC - U.S. Code, Title 35, Patents 
 
